3URWRFRO$ 6WDWLVWLFDO$QDO\VLV3ODQ9


3DJH


3URWRFRO$

$Q2SHQ/DEHO3KDVH%6WXG \RI3DOERFLFOLE2UDO&'.,QKLE LWRUSOXV$EUD[DQH¬ì
1DESDFOLWD[HOLQ3 DWLHQWVZLWK0HWDVWDWLF3DQFUHDWLF'XFWDO $GHQRFDUFLQRPD 


6WDWLVWLFDO$QDO\VLV3ODQ
6$3



9HUVLRQ 
$XWKRU 
'DWH  'HFHPEHU



PPD
Protocol A5481059 Statistical Analysis Plan V4 
 
 
Page 2 Document History 
Document Version  Date Summary of Changes  
Original SAP  July 29, 2015  Not applicable (N/A)  
Version 2  Nov 27, 2017 Incorporate the changes from protocol Amendment 
1 and Amendment 2.  
Major changes include: 
1. Addition of modified dose regimen  
cohorts, resulting in an increased sample  size of 
the overall study.  
2. A statement was included that will permit 
completion of dose escalation without 
determining the MTD, based on emerging  
safety data and upon agre ement between the 
investigators and the sponsor.  
3. Adding BOR detail definition . 
4. Modify RDI detail definition . 
5. Add in subgroup analysis for C a19a-9. 
6. Add in endpoint - Clinical Benefit Response  
7. Add in RDI calculation rules for MDR1 and 
MDR2.  
8. Provide details for dosing RDI calculation  
9. Clarification of minor discrepancies throughout 
the document . 
10. Modifications on Biomarkers, PRO, PK   
Version 3  May 8, 2018 1. Revise Biomarker population  
2. Add analysis on endpoint -CBR 
3. Add analysis on combined treatment group - 
DL3B (MTD cohort) + MTD  
4. Remove QTcS  
 
Version 4  December 6  
2018 1. Remove MDR expansion cohort , per 
Protocol Amendment 3  
2. Remover 3 -tier AE summary  
   
 
  

3URWRFRO$ 6WDWLVWLFDO$QDO\VLV3ODQ9


3DJHTABLE OF CONTENTS 
$0(1'0(176)52035(9,2869(56,216   
,1752'8&7,21    
6WXG\'HVLJQ    
'RVH(VFDODWLRQ&RKRUWV   
0RGLILHG'RVH5HJLPH Q0'5&RKRUWV   
([SDQVLRQ&RKRUWV   
6WXG\7UHDWPHQWV   
1DE3DFOLWD[HO$GPLQLVWUDWLRQ   
3DOERFLFOLE$GPLQLVWUDWLRQ   
6WXG\2EMHFWLYHV    
,17(5,0$1$/<6(6),1$/$1$/<6(6$1'81%/,1',1*   
+<327+(6(6$1''(&,6,2158/(6   
6WDWLVWLFDO+\SRWKHVHV   
6DPSOH6L]H'HWHUPLQDWL RQDQG6WDWLVWLFDO'HFLVLRQ5XOHV   
6DPSOH6L]H'HWHUPLQDWLRQ   
6WDWLVWLFDO'HFLVLRQ5XOHV   
$1$/<6,66(76    
6DIHW\$QDO\VLV6HW)XOO$QDO\VLV6HW   
3HU3URWRFRO$QDO\VLV6H W(YDOXDEOHIRU07'   
3HU3URWRFRO$QDO\VLV6HW(YD OXDEOHIRU$QWL7XPRU$FWLYLW LHV  
3KDUPDFRNLQHWLF$QDO\VLV6HWV   
%LRPDUNHU$QDO\VLV6HWV   
 
7UHDWPHQW0LVDOORFDWLRQV   
3URWRFRO'HYLDWLRQV   
(1'32,176$1'&29$5,$7(6   
6DIHW\(QGSRLQWV    
3ULPDU\(QGSRLQW   
6HFRQGDU\(QGSRLQWV   
6DIHW\   
/DERUDWRU\6DIHW\   
9LWDO6LJQV   CCI
3URWRFRO$ 6WDWLVWLFDO$QDO\VLV3ODQ9


3DJH(OHFWURFDUGLRJUDP(&*   
2WKHU6DIHW\$VVHVVPHQWV   
(IILFDF\   
3KDUPDFRNLQHWLFV   
%LRPDUNHUV   
   

   
+$1'/,1*2)0,66,1*9$/8(6   
0LVVLQJ'DWHV    
0LVVLQJ7XPRU$VVHVVPHQWV   
0LVVLQJ'DWDLQ3)6'HULYDWLRQ   
0LVVLQJ47F'DWD   
 
0LVVLQJ3.6DPSOHV   
0LVVLQJ'XSOLFDWH%LRPDUNHU'DWD   
67$7,67,&$/0(7+2'2/2*<$1'67$7,67,&$/$1$/<6(6   
6WDWLVWLFDO0HWKRGV    
P73,0HWKRG'RVH(VFDODWLRQ'H(VFDODWLRQ   
(VWLPDWLQJWKH0D[LPXP7ROHUDWHG'RVH   
$QDO\VHVIRU7LPHWR(YHQW'DWD   
$QDO\VHVRI%LQDU\'DWD   
$QDO\VHVRI&RQWLQXRXV'DWD   
$QDO\VHVIRU&DWHJRULFDO'DWD   
$QDO\VHVIRU47F'DWD   
'HULYHG$QDO\VLV9DULDEOHV   
$VVHVVPHQWRI47&RUUHFWLRQ0HWKRGV   
&KDQJHIURP%DVHOLQH'HILQLWLRQ   
2XWOLHU$QDO\VLV   CCI
CCI
CCI
3URWRFRO$ 6WDWLVWLFDO$QDO\VLV3ODQ9


3DJH6WDWLVWLFDO$QDO\VHV    
$QDO\VLVRI3ULPDU\(QGSRLQW'/7   
$QDO\VLVRI6HFRQGDU\6DIHW\(QGSRLQWV   
$GYHUVH(YHQWV   
/DERUDWRU\DEQRUPDOLWLHV   
(&*$QDO\VHV   
$QDO\VHVRI(IILFDF\(QGSRLQWV   
6WDQGDUG$QDO\VHV   
$QDO\VHVRI3KDUPDFRNLQHWLFDQG3 KDUPDFRG\QDPLF   
3DOERFLFOLE   
1DE3DFOLWD[HO   
$QDO\VLVRI3KDUPDFRNLQHWLFHQGSRLQWV   
3RSXODWLRQ3KDUPDFRNLQHWLF$QDO\VLVRU
3KDUPDFRNLQHWLF3KDUPDFRG\ QDPLF0RGHOLQJ   
$QDO\VHV%LRPDUNHU(QGSRLQWV   
  
6XPPDU\RI.H\&OLQLFDO(IILFDF\$QDO\VHV   
5()(5(1&(6    
$33(1',&(6    
&ULWHULDIRU'RVH(VFDODWLRQ   
5(&,675HVSRQVH(YD OXDWLRQ&ULWHULDLQ6ROLG7XPRUVYHU VLRQ
*XLGHOLQHV   
5XOHVIRU'HWHUPLQLQJ3)66WDWXVDQG'DWH   
'DWD'HULYDWLRQ'HWDLOV   
6WXG\7UHDWPHQW0RGLILFDWLRQDQG&RPSOLDQFH   
'RVH0RGLILFDWLRQ   
6XPPDUL]LQJ5HODWLYH'RVH5' DQG5HODWLYH'RVH,QWHQV LW\
5',   
.DUQRIVN\3HUIRUPDQFH6WDWXV   

 
 
/LVWRI$EEUHYLDWLRQ   CCI
CCI
CCI
3URWRFRO$ 6WDWLVWLFDO$QDO\VLV3ODQ9


3DJH
1.AMENDMENTS FROM PREVIOUS VERSION(S) 
7KH6$3ZDVDPHQGHGEDVH GRQWKH$PHQGPHQW$XJXVW 5HPRYH0'5
H[SDQVLRQFRKRUW
2.INTRODUCTION 
7KLVGRFXPHQWGHVFULEHVWKHSODQQHGVWDWLVWL FDODQDO\VHVIRU3U RWRFRO$GDWHG0D\
7KLVDQDO\VLVSODQLVPHDQWWRVXSSOHPHQWWKHVWXG\S URWRFRO$Q\GHYLDWLRQVIURP
WKLVDQDO\VLVSODQZLOOEHGHVFULEHGLQWKH&OLQLFDO6WXG\5HSR UW

&OLQLFDOGHYHORSPHQWRISDOERFLFOL ELQILUVWOLQHP3'$&EXLOGV XSRQUREXVWSUHFOLQLFDOGDWD
IURP3';PRGHOV 





7KLVFXUUHQWVWXG\DLPVWRLQYHVWLJDWHWKHVDIHW\DQGWROHUDELO LW\RIWKHFRPELQDWLRQRI
SDOERFLFOLESOXVQDESDFOLWD[HOLQSDWLHQWVZLWKP3'$&
2.1.Study Design 
7KLVLVD3KDVHRSHQODEHOPXOW LFHQWHUPXOWLSOHGRVHGRV HHVFDODWLRQVDIHW\
SKDUPDFRNLQHWLFDQGSKDUPDFRG\QD PLFVWXG\RISDOERFLFOLELQFRP ELQDWLRQZLWKQDE
SDFOLWD[HOLQVHTXHQWLDOFRKRUWVRIDGXOWSDWLH QWVZLWKP3'$&ZLWKPD[LPX PWROHUDWHGGRVH
07'H[SDQVLRQFRKRUWV$SSUR[LP DWHO\SDWLHQWVDUHH[ SHFWHGWREHHQUROOHGLQ
WKHRYHUDOOVWXG\7KHVWXG\KDVVHYHUDOSDUWV
2.1.1.Dose Escalation Cohorts  
&RQVHFXWLYHFRKRUWVRISDWLHQWVZLOO UHFHLYHHVFDODWLQJGRVHVR IRUDOSDOERFLFOLELQ
FRPELQDWLRQZLWKLQWUDYHQRXVQDESDFO LWD[HOLQGD\F\FOHV 7KHVWDUWLQJGRVHVRI
SDOERFLFOLEZLOOEHPJDGPLQLVW HUHGRQ'D\RIHDFKF\F OHGRVLQJVFKHGXOH
7KHVWDUWLQJGRVHRIQDE3LVPJPDGPLQLVWHUHGZHHNO\IRUZHHNVRXWRIHDFKGD\
F\FOH7KHREVHUYDWLRQSHULRGIRU GRVHOLPLWLQJWR[LFLWLHV'/ 7VZLOOEHIURP'D\XQWLO
SUHGRVH&\FOH'D\'D\ DQG'D\ZLOOQRWEHLQFOXGHG LQWKH'/7REVHUYDWLRQ
SHULRG3KDUPDFRNLQHWLF3. DQGSKDUPDFRG\QDPLF3'SURSHUW LHVRISDOERFLFOLEDQG
QDESDFOLWD[HOZLOOEHDVVH VVHG8SWRDSSUR[LPDWHO\SDWLHQ WVZLOOEHHQUROOHG
'RVHHVFDODWLRQDQGGHHVFDODWL RQZLOOIROORZD[PDWUL[¬≥8S DQG'RZQ¬¥GHVLJQEDVHGRQ
DPRGLILHGWR[LFLW\SUREDELOLW\LQWHUYDOP73,PHWKRGXVLQJG RVHVRISDOERFLFOLEDQGQDE
SDFOLWD[HODVVKRZQLQWKH7DEOHDQG)LJXUHEHORZ,QW KLVGRVLQJDOJRULWKPWKHUHDUH
XSWRSRWHQWLDOGRVHFRPELQDWLRQVH[FOXGLQJ'/CCI
Protocol A5481059 Statistical Analysis Plan V4 
 
 
Page 7 Table 2.1 Potential Palbociclib and Nab -Paclitaxel Dose Combinations  
Dose Level  Palbociclib  
(oral, mg/day)  
Days 1-21 within a 
28-day cycle  Nab-Paclitaxel  
(IV, mg/m2/day) 
Weekly dose for 3 weeks 
within a 28-day cycle  
-1 50 100 
1 (starting dose level)  75 100 
1.5 50 125 
2A 100 100 
2B 75 125 
3A 125 100 
3B 100 125 
4 125 125 
 
Alternate dosing schedules for palbociclib may be explored based on emerging PK, PD, and 
safety data. 
The 2x3 matrix approach allows for parallel dose level cohorts consisting of different dose 
combina
tions. Dose escalations and de-escalations will be called for based upon assessment 
of DLTs and other adverse events during the first treatment cycle (28 days). See Section 
8.1.1. for a detailed description of the mTPI dose-escalation method. 
Figur
e 2.1 Palbociclib and Nab-Paclitaxel Combination Dose Escalation and De-
Escalation Sequence 
palbociclib 75mg + 
nab-paclitaxel 100mg/m2palbociclib 100mg + nab-paclitaxel 100mg/m2
palbociclib 75mg + nab-paclitaxel 125mg/m2palbociclib 100mg + nab-paclitaxel 125mg/m2palbociclib 125mg + nab-paclitaxel 125mg/m2
palbociclib 50mg + 
nab-paclitaxel 100mg/m2palbociclib 125mg + 
nab-paclitaxel 100mg/m2
Level 1 (start)
Level -1Level 2A
Level 2BLevel 3ALevel 3BLevel 4
palbociclib 50mg + 
nab-paclitaxel 125mg/m2Level 1.5
 
The sequential dose escalation scheme and the rules for determining dose escalation, de-
esca
lation, or ‚Äòstay‚Äô (i.e. enroll an additional group of patients to the current DL) at any given 
dose level are described in Appendix 10.2.   

Protocol A5481059 Statistical Analysis Plan V4 
 
 
Page 8 2.1.2. Modified Dose Regimen (MDR) Cohort(s) 
 Per Protocol Amendment 1, additional 2 cohorts of patients will be enrolled into alternative 
dose reg
imens at doses lower than the dose levels tested in dose escalation. The following 
dose regimens will be tested: 
ÔÇ∑ Modified Dose Regimen 1 (MDR1)-75 mg palbociclib once daily on Days 1-21 of 
eac
h 28-day cycle, plus nab-P 125 mg/m2 biweekly in each 28-day cycle. 
ÔÇ∑ Modified Dose Regimen 2 (MDR2)-75 mg palbociclib continuous dosing, once daily, 
plus nab-P 100 mg/m2 biweekly in each 28-day cycle. 
 
At least 6-9 patients will be enrolled into each MDR cohort. Patients enrolled into MDR 
cohorts will a
lso be assessed for DLTs. If the number of patients with a DLT falls into the 
mTPI ‚Äú
De-escalateescalate ,‚Äù category for one or both MDR cohorts, cohort(s) will not 
move forward into expansion. The MDR cohort with a DLT rate <0.33 in at least 9 DLT 
evaluable patient spatients will be considered to move forward into  expansion.  
 
2.1.3. Expansion Cohort(s) 
ÔÇ∑ MTD Expansion Cohort(s) 
Whe
n the MTD(s) of palbociclib plus nab-paclitaxel has been estimated with 
confidenc
e, enrollment will proceed into 1 or 2 MTD expansion cohort(s) of up to 20 patients 
each at the MTD(s). Patients will receive the same dosing regimen as in the dose escalation 
cohorts (pa
lbociclib 3/1 schedule and weekly n ab-P for 3 weeks in each 28-day cycle). 
 
 
The objecti
ve of the expansion cohort(s) are to provide additional information on safety, 
tolera
bility, biomarkers, PD activity and PK/PD relationship for the combination regimen in 
order to determine the recommended phase 2 dose (RP2D).  The expansion cohort(s) will 
only e
nroll patients who have not received previous treatment for their metastatic disease in 
order to evaluate preliminary activity of the combination in patients in the target patient 
population.  
 
 
2.1.4. Stud
y Treatments 
All patients will receive nab-paclitaxel and palbociclib.   
2.1.4.1. Nab-Paclitaxel Administration 
To allow for PK evaluation of nab-paclitaxel administered alone, nab-paclitaxel will be 
administ
ered on Day -2 for Cycle 1 only.  Subsequent cycles will administer both nab-
pacli
taxel and palbociclib on Day 1.  Alternate dosing schedules for palbociclib may be 
explore
d based on emerging PK, PD, and safety data. 
Nab-P will be administered in the clinic. Patients will receive nab-P as an intravenous 
infusion ove
r 30 minutes. Nab-P will be administered based on the assigned dose regimen 
(eithe
r once weekly for 3 weeks, or biweekly in each 28-day cycle). In Cycle 1, nab-P will 

Protocol A5481059 Statistical Analysis Plan V4 
 
 
Page 9 start on Day -2 in order to evaluate the pharmacokinetics of nab-P administered alone and in 
combination with palbociclib (Figure 2.2). On Day 13, nab-P and palbociclib should be 
dosed at approximately the same time. For cycle ‚â•2, both palbociclib and nab-P 
administration will start on Day 1, and palbociclib dosing should occur as close as possible to 
the start of infusion of nab-P. Treatment with IP will continue until disease progression, 
unacceptable toxicity, or consent withdrawal. 
Figure 2.2 Palbociclib and Nab-Paclitaxel Dose Combination Schema  
Dose Escalation and MTD Expansion Cohorts 
 
Modified Dose Regimen 1 (palbociclib 3/1 schedule, biweekly nab- P) 
 
Modified Dose Regimen 2 (continuous palbociclib, biweekly nab- P) 
 
2.1.4.2. Palbociclib Administration 
Palbociclib dosing will be administered orally. The palbociclib dosing schedule is determined 
by c
ohort assignment, either 3/1 schedule (once a day for 21 consecutive days, followed by 7 
days off treatment) or continuous dosing in each 28-day before starting the next cycle (for 
MDR2 cohort). Each patient will receive enough palbociclib to support their treatment cycle 
duration e
ach month. Patients should be instructed to swallow palbociclib capsules whole 
and not to manipulate or chew them prior to swallowing. No capsule should be ingested if it 
is broken, cra
cked, or otherwise not intact. Patients should be encouraged to take their dose at 
approxim
ately the same time each day. Patients should be instructed to record daily 
administ
ration of the investigational product in a patient diary provided by the sponsor. 

3URWRFRO$ 6WDWLVWLFDO$QDO\VLV3ODQ9


3DJH3DWLHQWVVKRXOGWDNHSDOERFLFOLEZLWKIRRG
3DWLHQWVZLOOEHWUHDWHGDVORQJD VWKH\DUHFOLQLFDOO\EHQHILW LQJIURPLQYHVWLJDWLRQDOSURGXFWV
,3ZLWKRXWXQDFFHSWDEOHWR[LFLW\REMHFWLYHGLVHDVHSURJUHVVL RQRUZLWKGUDZDORIFRQVHQW
$PRGLILHGYLVLWVFKHGXOHZLOOEHLPSOH PHQWHGIRUSDWLHQWVZKR DUHRQLQYHVWLJDWLRQDO
SURGXFW,3IRUPRUHWKDQ\HD UVVHH6FKHGXOH$FWLYLWLHVLQ $SSHQGL[
3DWLHQWVZKRGLVFRQWLQXHLQYHVWLJDWL RQDOSURGXFW,3IRUUHDVR QVRWKHUWKDQUDGLRJUDSKLFDOO\
DQGRUFOLQLFDOO\LHIRU SKRWRJUDSKHGRUSDOSDEOHOHVLRQVG RFXPHQWHG3'DVSHU5(&,67
YZLOOFRQWLQXHWRKDYHWXPRUD VVHVVPHQWSHUIRUPHGGXULQJW KHIROORZXSYLVLWVHYHU\
ZHHNVXQWLO5(&,67GHILQHGGLVHD VHSURJUHVVLRQLQLWLDWLRQRIQ HZDQWLFDQFHUWKHUDS\RU
GLVFRQWLQXDWLRQRISDWLHQWIU RPRYHUDOOVWXG\SDUWLFLSDWLRQH JGHDWKSDWLHQW
VUHTXHVWORVW
WRIROORZXSZKLFKHYHURFFXUVILUVW3DWLHQWVGLVFRQWLQXLQJW KHWUHDWPHQWSKDVHZLOOHQWHUD
IROORZXSSHULRGGXULQJZKLFKVXUYLYD ODQGQHZDQWLFDQFHUWKHU DS\LQIRUPDWLRQZLOOEH
FROOHFWHGHYHU\PRQWKIURPWKHODVWGRVHRIVWXG\GUXJ
(IILFDF\DQDO\VHVZLOOEHSH UIRUPHGXVLQJWKHORFDOUDGLRORJLVW ¬∂VLQYHVWLJDWRU¬∂VWXPRU
DVVHVVPHQWVDVWKHSULPDU\GDWDVRXUFH 3DWLHQWVZLOOXQGHUJRV WXG\UHODWHGVDIHW\HIILFDF\
DQG3.DVVHVVPHQWVDVRXWOLQHGLQWKH6FKHGXOHRI$FWLYLWLHV 

%ORRGWXPRUELRSVLHVRSWLRQDODQG RSWLRQDOIRUGRVHHVFDO DWLRQDQG
0'50'5DQG0'5FRKRUWVZLOOEHWDNH QZKLOHRQWUHDWPHQWDQG DWWKHHQGRI
WUHDWPHQW







2.2.Study Objectives 
3ULPDU\2EMHFWLYH
x7RDVVHVVWKHVDIHW\DQGWROHUDELO LW\RISDOERFLFOLELQFRPELQD WLRQZLWKQDESDFOLWD[HO
LQSDWLHQWVZLWKPHWDVWDWLFSDQFUHDWLFGXF WDODGHQRFDUFLQRPDLQ RUGHUWRHVWLPDWHWKH
PD[LPXPWROHUDWHGGRVH07'DQGVH OHFWWKHUHFRPPHQGHG3KDVH GRVH53'
6HFRQGDU\2EMHFWLYHV
x7RHYDOXDWHWKHRYHUDOOVDIHW\SURILOHRISDOERFLFOLELQFRPELQ DWLRQZLWKQDE
SDFOLWD[HO
x7RFKDUDFWHUL]HWKHPXOWLSOH GRVHSKDUPDFRNLQHWLFVRISDOERFLFO LEZKHQDGPLQLVWHUHG
LQFRPELQDWLRQZLWKQDESDFOLWD[HOCCICCI
CCI
3URWRFRO$ 6WDWLVWLFDO$QDO\VLV3ODQ9


3DJHx7RHYDOXDWHWKHHIIHFWRI SDOERFLFOLERQSKDUPDFRNLQHWLFVRIWR WDOSDFOLWD[HOZKHQ
QDESDFOLWD[HOLVDGPLQLVWHUHGLQFRPELQDWLRQZLWKSDOERFLFOLE 
x7RHYDOXDWHWKHDQWLWXPRU HIIHFWRISDOERFLFOLELQFRPELQDWLRQ ZLWKQDESDFOLWD[HOLQ
SDWLHQWVZLWKP3'$&
x7RHYDOXDWHWKHSKDUPDFRG\QDPLFHI IHFWRISDOERFLFOLEDQGQDES DFOLWD[HOLQSDWLHQWV
ZLWKP3'$&
x7RFKDUDFWHUL]HFDQGLGDWHELRPD UNHUVRIVHQVLWLYLW\RUUHVLVWDQ FHLQSUHWUHDWPHQW
WXPRUWLVVXHLQFOXGLQJ5EDQGSH[ SUHVVLRQWKDWPD\DLGLQ WKHLGHQWLILFDWLRQRI
SDWLHQWVXESRSXODWLRQVPRVWOLNHO\WREHQHILWIURPWUHDWPHQW


 


 

 

 

 
 

3.INTERIM ANALYSES, FINAL A NALYSES AND UNBLINDING 
7KLVLVDQRSHQODEHOVLQJOHDUPWULDOIRUZKLFKQRIRUPDOLQW HULPDQDO\VLV LVSODQQHG7KH
ILQDODQDO\VLVZLOOEHSHUIRU PHGDIWHUWKHODVWSDWLHQWODVWYL VLWKRZHYHUHDUOLHUDQDO\VHVRI
WKHGDWDPD\EHSHUIRUPHGIRUSXEOLFDWLRQDQGUHJXODWRU\UHSRUW LQJSXUSRVHV 
4.HYPOTHESES AND DECISION RULES 
4.1.Statistical Hypotheses 
7KHHPSKDVLVRIWKHILQDODQD O\VHVZLOOQRWEHRQK\SRWKHVLVWH VWLQJEXWUDWKHURQHVWLPDWLRQRI
NH\VXPPDU\VWDWLVWLFV 
4.2.Sample Size Determination and Statistical Decision Rules 
4.2.1.Sample Size Determination 
'XHWRWKHG\QDPLFQD WXUHRIWKH%D\HVLDQDOORFDWLRQSURFHGXUH WKHVDPSOHVL]HRIWKH8S
DQG'RZQPDWUL[GHVLJQXVLQJWKHP73 ,DSSURDFKFDQQRWEHGHWHUP LQHGLQDGYDQFH,WLV
HVWLPDWHGWKDWDSSUR[LPDWHO\ '/7HYDOXDEOHSDWLHQWVZLOO EHHQUROOHGLQWKHGRVH
HVFDODWLRQVWDJHLQRUGHUWRKDYHD UHOLDEOHDQGDFFXUDWHHVWLP DWHRIWKH07'V7KH07'
H[SDQVLRQFRKRUWVZLOOHQUROO XSWRDSSUR[LPDWHO\UHVSRQVH HYDOXDEOHSDWLHQWVDWWKH
HVWLPDWHG07'VCCI
Protocol A5481059 Statistical Analysis Plan V4 
 
 
Page 12 Based on probability theory, a sample size of approximately 20 patients per expansion cohort 
at the MTD(s) will ensure the estimates of any binary variable have a 95% confidence 
interva
l of maximum width ÔÇ£0.45. A sample size of approximately 60 patients (at any dose) 
also enables detection of any unexpected toxicity that occurs at 5% rate (in a non-dose-
dependent fashion) with a probability of 0.95, and that occurs at 10% rate with a probability 
of 0.998.   
4.2.2. Stat
istical Decision Rules 
Dose Escalation Cohorts  
The dose escalation/de-escalation rules will follow the mTPI method (see Section 8.1 for a 
detailed description). Briefly, the mTPI method relies upon a statistical probability algorithm, 
calculated using data from all patients treated at the same dose level (and not simply those in the 
current cohort) to determine whether future cohorts should involve dose escalation, no change in 
dose, or dose de-escalation. 
The MTD determination will be based on the observed toxicity rates among all evaluable 
patients at any given DL.  When dose escalation is stopped, the highest DL with an observed 
DLT 
rate <33% (in at least 9 DLT-evaluable patients) will be considered the MTD.  It is 
possible that more than one MTD will be determined, in which case a decision will be made 
to expand one or both MTDs in order to determine the RP2D. 
The dose e
scalation portion of the study is completed when at least 9 evaluable patients have 
been tre
ated at the highest DL associated with a DLT rate <33%. It is estimated that 
approxim
ately 30 ‚ÄòDLT-evaluable‚Äô patients will be enrolled to reach n = 9 ‚ÄòDLT-evaluable‚Äô 
pati
ents at the estimated MTD. 
Dose escalation may be completed without determining the MTD based on emerging safety 
data, and upon agreement between the investigators and the sponsor. 
Modified Dose Regimen Cohorts  
Patients enrolled into MDR cohorts will also be assessed for DLTs. If the number of patients 
with a DLT falls into the ‚ÄúDe-escalate‚Äù category in one or both MDR cohorts, the cohort(s) 
will not move forward into expansion. The MDR cohort with a DLT rate <0.33 in at least 9 
DLT evaluable patient will be considered to move forward into expansion. 
 
Expansion Cohorts 
ÔÇ∑ MTD Expansion Cohort(s): 
Once the MTD for the combination has been defined in the dose-escalation cohorts, up to 20 
patients who have not received previous treatment for their metastatic disease  will be enrolled 
and tr
eated in the MTD expansion cohort. Patients will receive the same dosing regimen as in 
the dose escalation cohorts (palbociclib 3/1 schedule and weekly nab-P for 3 weeks in each 
28-day cycle).  
 

3URWRFRO$ 6WDWLVWLFDO$QDO\VLV3ODQ9


3DJH
7KHREMHFWLYHVRIWKHH[SD QVLRQFRKRUWVDUHWRSURYLGHDGGLWLRQ DOLQIRUPDWLRQRQVDIHW\
WROHUDELOLW\ELRPDUNHUV3'D FWLYLW\DQG3.3'UHODWLRQVKLSI RUWKHFRPELQDWLRQUHJLPHQLQ
RUGHUWRGHWHUPLQHWKH53'
5.ANALYSIS SETS 
5.1.Safety Analysis Set (Full Analysis Set) 
7KHVDIHW\DQDO\VLVVHWLQFOXGHVD OOHQUROOHGSDWLHQWVZKRUHFH LYHDWOHDVWRQHGRVHRIHLWKHU
LQYHVWLJDWLRQDOSURGXFW7KHVDIHW\DQDO\VLVVHWZLOODOVREHX VHGIRUHIILFDF\ DQDO\VHV
5.2.Per Protocol Analysis Set Evaluable for MTD 
7KHSHUSURWRFRODQDO\VLVVHWLQFOXGHVD OOHQUROOHGSDWLHQWVZK RUHFHLYHDWOHDVWRQHGRVHRI
LQYHVWLJDWLRQDOSURGXFWDQGZKRGRQRWKDYHPDMRUWUHDWPHQWGHY LDWLRQVGXULQJWKHILUVWF\FOH
RIWUHDWPHQW3DWLHQWVZL WKPDMRUWUHDWPHQWGHYLDWLRQVLQWKH ILUVWF\FOHDUHQRWHYDOXDEOHIRU
WKH07'DVVHVVPHQWDQGZLOOEHUH SODFHGDVQHHGHGWRSHUPLW07' HVWLPDWLRQ0DMRU
WUHDWPHQWGHYLDWLRQVLQFOXGH DGPLQLVWUDWLRQRIOHVVWKDQRI WKHSODQQHGGRVHRI
SDOERFLFOLERUOHVVWKDQGRVHVRIQDE SDFOLWD[HOIRUUHDVRQV RWKHUWKDQWUHDWPHQWUHODWHG
WR[LFLW\LQ&\FOH
5.3.Per Protocol Analysis Set Evaluable for Anti-Tumor Activities 
$OOHQUROOHGSDWLHQWVZKRDUHHOLJLEOHUHFHLYHVWXG\WUHDWPHQW KDYHDGHTXDWHEDVHOLQH
DVVHVVPHQWVDQGDWOHDVWRQ VWXG\WXPRUDVVH VVPHQWSULRUWRD Q\QHZDQWLFDQFHUWKHUDSLHVZLOO
EHFRQVLGHUHGHYDOXDEOHIRUDQWLWXPRUDFWLYLWLHV3DWLHQWVZKR DUHWUHDWHGDQGGLVFRQWLQXHGIURP
WUHDWPHQWSULRUWRWKHILUVWRQ VWXG\WXPRUDVVHVVPHQWEHFDXVH RIGLVHDVHSURJUHVVLRQZLOOEH
FRQVLGHUHGHYDOXDEOHIRUHIILFDF\DQGFRXQWHGDVIDLOXUHV'HI LQLWLRQIRUDGHTXDWHEDVHOLQHWXPRU
DVVHVVPHQWLVUHSRUWHGLQ$SSHQGL[ 
5.4.Pharmacokinetic Analysis Sets 
7KH3.SDUDPHWHUDQDO\VLVSRSXODWLRQLVGHILQHGDVDOOHQUROOHG SDWLHQWVWUHDWHGZKRKDYH
VXIILFLHQWLQIRUPDWLRQWRHVWLPDWH DWOHDVWRIWKH3.SDUDPHW HUVRILQWHUHVWDQGKDYHQR
PDMRUSURWRFROGHYLDWLRQVDIIHFWLQJ3.DVVHVVPHQW
7KH3.FRQFHQWUDWLRQSRSXODWLRQL VGHILQHGDVDOOHQUROOHGSDWL HQWVZKRDUHWUHDWHGDQGKDYH
DWOHDVWDQDO\WHFRQFHQWUDWLRQ
5.5.Biomarker Analysis Sets 
7KHELRPDUNHUDQDO\VLVVH WLVGHILQHGDVDOOSDWLHQWVZKRKDYH UHFHLYHGDWOHDVWRQHGRVHRI
LQYHVWLJDWLRQDOSURGXFWDQGZKRKDYH DWOHDVWRQHEDVHOLQHELRP DUNHUDVVHVVPHQW
 

CCI
Protocol A5481059 Statistical Analysis Plan V4 
 
 
Page 14 5.7. Treatment Misallocations  
Not applicable. 
5.8. Protocol Deviations 
All deviations will be described when they appear and relate to the statistical analyses or 
analysis populations. 
6. ENDPOINTS AND COVARIATES 
6.1. S
afety Endpoints 
6.1.1. Pri
mary Endpoint  
First cycle DLTs 
Severity of adverse events will be graded according to NCI CTCAE version  4.03.  For the 
purpose of do
se escalation, any adverse events occurring in the first cycle of treatment (Day 
1 until pre-dose Cycle 2 Day 1) which are attributable to palbociclib, nab-paclitaxel, or to the 
combina
tion of palbociclib and nab-paclitaxel will be classified as DLTs.  Adverse events 
that occur
 between Cycle 1 Day -2 after nab-paclitaxel administration and Cycle 1 Day 1 
(prior to palbociclib dosing) will not be considered a DLT.  The following adverse events 
will be considered a DLT: 
ÔÇ∑ Hematologic: 
o Grade 4 neutropenia lasting > 4 days; 
o F
ebrile neutropenia (defined as neutropenia Grade ‚â•3 [ANC <1000 cells/mm3] 
and a
 body temperature ‚â•38.5¬∞C) requiring antibiotic or antifungal treatment; 
o Any Grade 4 thrombocytopenia (<25,000/mm3 or <25.0 x 109/L). 
ÔÇ∑ Non-hematologic: Grade ÔÇ≥3 toxic ities, except those that have not been maximally 
treated (e.g., nausea, vomiting, diarrhea).  
ÔÇ∑ Other:  
o An
y adverse event that causes a palbociclib treatment interruption of greater than 
7 consecutive days; or causes any combination of interruption/reduction for ‚â•14 
days;
 
o Any adverse event that causes omission or reduction of at least 2 of the 3 weekly 
doses of na
b-P 
 
6.1.2. Secondary Endpoints  
6.1.2.1. Safety  
Safety assessment will consist of monitoring of all AEs, including SAEs, regular monitoring 
of hematolog
y, serum chemistry, and routine monitoring of ECGs, physical examinations, 
vital signs, and ECOG performance status.  
Overall
 safety profile as characterized by type, frequency, severity of adverse events as 
graded by NCI Common Toxicity Criteria for Adverse Events version 4 (NCI CTCAE 

Protocol A5481059 Statistical Analysis Plan V4 
 
 
Page 15 v.4.03), timing, seriousness,  and relationship to study therapy, and laboratory abnormalities 
observed. 
 
Base
line signs and symptoms will be recorded at baseline and then reported as adverse events 
during the trial if they worsen in severity or increase in frequency.  
Adverse events (AEs), hematology, blood chemistry will be assessed as described in the 
Schedule of Activities of the protocol. 
Adverse events will be classified using the MedDRA classification system. The severity of 
the toxicities will be graded according to the NCI CTCAE version 4.03. For labs without 
CTCAE grade definitions, results are summarized as normal, abnormal (per Pfizer Data 
Standards (PDS)) or not done. For other AEs without specific CTCAE definitions, results are 
identified according to CTCAE ‚Äúother‚Äù categories.  
Adverse events leading to death or discontinuation of trial treatment, events classified as NCI 
CTCAE v.4.03 Grade 3 or higher, trial drug related events, and serious adverse events will be 
considered with special attention. 
The hematologic and chemistry laboratory results will be graded according to the NCI 
CTCAE v.4.03 seve
rity grade. For parameters for which an NCI CTCAE v.4.03 scale does 
not exist, 
the frequency of patients with values below, within, and above the normal range for 
the local 
lab will be summarized. 
Patients who start treatment are assessed for toxicities up to 28 days after the final dose of 
treatment or start of new treatment (whichever comes first). Toxicities observed beyond 28 
days and recorded in the database per Sponsor's agreement will be included in the 
summaries. 
6.1.2.1.1. Treatment Emergent Adverse Event 
An adverse event is considered treatment emergent if: 
ÔÇ∑ The event occurs for the first time after the start of study treatment and before 28 days 
afte
r final dose of study treatment and was not seen prior to the start of treatment or 
ÔÇ∑ The event was seen prior to the start of treatment but increased in NCI CTCAE v.4.0 
grade during study treatment. 
ÔÇ∑ Disease progression is not considered a treatment emergent adverse event unless the 
patient dies of disease prior to 28 days after discontinuation of treatment. 
6.1.2.1.2. Treatment Related Adverse Event 
Adverse events defined as treatment emergent adverse events with cause possibly, probably 
or definitely related to treatment as judged by the investigator are defined as treatment related 
adverse events. Events that are continuation of baseline abnormalities are not considered 
treatment related unless there is an increase in grade, or if there is an increase following a 
decrease, and the increase is judged by the investigator to be caused by the treatment. 

Protocol A5481059 Statistical Analysis Plan V4 
 
 
Page 16 6.1.2.2. Laboratory Safety  
Laboratory assessment will be assigned to cycles based on the collection date of the sample 
relative to the start dates of cycles from the study drug administration as described in the 
Schedule of Activities table in Appendix 10.1. 
Labo
ratory abnormalities as characterized by type, frequency, severity (as graded by NCI 
CTCAE version 4.03)
, and timing; 
Baseline evaluations for laboratory are those collected 
ÔÇ∑ Within 28 days prior to or on first day of study drug and 
ÔÇ∑ I
f there is more than one baseline evaluation, closest to but any time prior to the 1st 
dosing
 on the first day of study treatment. 
 
Haematology, blood chemistry, coagulation, and urinalysis will be drawn at the time points 
described in the Schedule of Activities and analyzed at local laboratories. 
Additional blood tests should be performed where needed for the purpose of evaluating 
potential DLTs or other adverse events. In particular, if a patient has Grade 3 neutropenia, 
complete blood count (CBC) should be performed every 24-48 hours. 
Urinalysis will be conducted via urine dipstick for urine protein: if the result is positive, a 24-
hour collection and microscopic reflex testing will be conducted. 
Special blood sample for CA19-9 will also be collected. 
Blood te
sts will include the following: 
Table 6.1 Laboratory Tests 
Hematology  Chemistry Coagulation  Urinalysis Pregnancy Test  
Hemoglobin  ALT PT or INR Urine dipstick for 
urine protein: If 
positive, further 
diagnostic testing 
will be performed as 
clinically indicated  For female patients 
of childbearing 
potential,  serum or 
urine  Platelets AST PTT 
WBC Alk Phosphatase  aPTT 
Absolute Neutrophils  Sodium  
Absolute Lymphocytes  Potassium  
Absolute Monocytes  Magnesium   Urine dipstick for 
urine blood: If 
positive collect a 
microscopic (Reflex 
Testing)  
Absolute Eosinophils  Chloride   
Absolute Basophils  Total Calcium    
 Total Bilirubin*    
 BUN or Urea    
 Creatinine   
 Uric Acid   
 Glucose (non -fasted)   
 Albumin    
 Phosphorous or 
Phosphate    

Protocol A5481059 Statistical Analysis Plan V4 
 
 
Page 17  Amylase (if 
available)     
 Lipase (if available)     
*For potential Hy‚Äôs Law cases, in addition to repeating AST and ALT, laboratory tests should include albumin, 
creatine kinase, total bilirubin, direct and indirect bilirubin, gamma-glutamyl transferase, prothrombin time 
(PT)/INR, and alkaline phosphastase.  In addition, acetaminophen levels should be considered. 
 
6.1.2.3. Vital Signs 
Patients will have a physical exam to include, weight, vital signs (pulse rate and blood 
pressure), assessment of Karnofsky (see Ap pendix 10.8) performance status, and height; 
height wil
l be measured at screening only.   
6.1.2.4. Electrocardiogram (ECG) 
All ECGs will be performed using a 12-lead (with a 10-second rhythm strip) tracing.  ECG 
measurements will include PR interval, QT interval, RR interval, and QRS complex.  It is 
preferable that the machine used has a capacity to calculate the standard intervals 
automatically.  
ECG interval readings by the ECG recorder‚Äôs algorithm will be read and interpreted at the 
investiga
tional site for eligibility determination and patient safety monitoring and 
documentation stored in the source documents.  
Triplicate ECGs will be performed for all patients.  
ÔÇ∑ All ECGs should be obtained after a fast of at least 1 hour .  Whe n scheduled at the 
same nominal time
/visit, triplicate ECGs should be collected prior to any blood draws 
for PK, biomarkers, or safety labs and prior to placement of the IV line for nab -
paclitaxel administration. 
ÔÇ∑ Triplicate ECGs will be obtained for safety monitoring at Screening, and 0 hour 
(pre
-dose) on C1D-2, C1D13, C2D1 and C2D15, then on Day 1 of Cycles 4 and 7.  
ECGs will be obtained at the time of End of Treatment or Withdrawal.  ECGs beyond 
Cycle 7 will be performed as clinically indicated. 
ÔÇ∑ Additional ECGs may be performed as clinically indicated at any time. 
For
 the purpose of the study, triplicate ECGs are defined as three consecutive ECGs 
performed approximately 2 minutes apart but within 10 minutes for all 3 ECGs at the 
protocol spec
ified timepoints (see Schedule of Activities Section 10.1. for details) to 
dete
rmine the mean QTc interval.   
If patient experiences a cardiac or neurologic AE (specifically syncope, dizziness, seizures, 
or stroke), an ECG (triplicate) should be obtained at the time of the event.  
When matched with PK sampling, ECG must be carried out before PK sample drawing such 
that the PK samples are collected at the nominal time (i.e. the timing of the PK collections 
overrides the timing of the ECG collections. 

Protocol A5481059 Statistical Analysis Plan V4 
 
 
Page 18 6.1.2.5. Other Safety Assessments 
A full physical examination including an examination of all major body systems (including 
general appearance, head, ears, eyes, nose, mouth, throat, neck, thyroid, lungs, heart, breasts, 
abdomen, and musculoskeletal), height (at Screening only), weight, blood pressure and pulse 
rate which ma
y be performed by a physician, registered nurse or other qualified health care 
provider, will be required at screening, and Cycle 1 Day -2 and Cycle 2 Day 1.  
Symptom directed physical examinations, blood pressure and pulse rate will be performed at 
subsequent visits according to the Schedule of Activities. 
6.1.2.6. Efficacy 
Objective Response (OR) is defined as the overall complete response (CR) or partial 
response (P
R) according to the Response Evaluation Criteria in Solid Tumors (RECIST 
version 1.1; Appendix
 10.4).  Objective Response Rate (ORR ) is defined as the proportion 
of patients with a best overall response (BOR based on confirmed responses as described in 
Appendix 10.4)
 of CR or PR relative to all anti-tumor evaluable patients. Patients who do not 
have on-
study radiographic tumor re-evaluation, who receive anti-tumor treatment other than 
the study medication prior to reaching a CR or PR, or who die, progress, or drop out for any 
reason prior to reaching a CR or PR will be counted as non-responders in the assessment of 
ORR. Clinical Benefit Response (CBR) is  defined as a patient with a BOR of CR or PR at 
any
 time, or non-CR/non-PD or SD for at least 16 weeks from start date.  
Tumor response w
ill be determined from tumor assessment data (as described in Appendix 
10.4).   
Duration of Response (DR)  is defined as the time from the first documentation of objective 
tumor r
esponse (CR or PR) to the first documentation of disease progression or to death due 
to any cause, whichever occurs first.  If tumor progression data include more than 1 date, the 
first date will be used.  DR will be calculated as [the date response ended (i.e. date of PD or 
death) ‚Äì first CR or PR date + 1)]/30.4.  DR will only be calculated for the subgroup of 
patie
nts with an objective tumor response. 
Pati
ents last known to be 1) alive and 2) progression-free, are censored at the date of the last 
objective
 disease assessment that verified lack of disease progression. In addition, 
ÔÇ∑ If a new anti-cancer treatment is started prior to progression and prior to 28 days after 
discontinua
tion of treatment, then censorship is at the date of the last objective 
disease a
ssessment that verified lack of disease progression prior to the new 
treatment.  
ÔÇ∑ If patients are removed from the study (withdrew the consent, lost to follow up, etc.) 
prior to progression and death, then censorship is at the date of the last objective 
disease assessment that verified lack of disease progression. 
ÔÇ∑ Patients with documentation of progression or death after an unacceptably long 
inte
rval (>2 consecutive assessments) since the last tumor assessment will be 
censored at the time of last objective assessment documenting no progression. 
 

Protocol A5481059 Statistical Analysis Plan V4 
 
 
Page 19  
Progression Free Survival (PFS)  is defined as the time from the date of first dose  to the 
date of the f
irst documentation of objective tumor progression as per RECIST v.1.1 or death 
due to any
 cause in the absence of documented PD, whichever occurs first.  If tumor 
progressi
on data include more than 1 date, the first date will be used.  PFS (in months) will 
be calculated as (first event date ‚Äì first dose date +1)/30.4.  
Tumor assessments will be pe
rformed every 8 weeks (¬± 7 days) (12 weeks (¬± 7 days) for 
Cycles ‚â• 6) from first dose until radiographically and/or clinically (for photographed or 
palpable lesions) doc
umented PD as per RECIST v.1.1, initiation of new anticancer therapy, 
or discontinuation of patient from overall study participation (e.g., death, patient's request, 
lost to follow up). 
Imaging assessments are to be scheduled using the first dose date as the reference date for all 
time-points and are NOT to be scheduled based on the date of the previous imaging time-
point. Patients who discontinue study treatment for reasons other than radiographically 
and/or clinically (for photographed or palpable lesions) documented disease progression as 
per RECIST definitions will continue to have tumor assessment performed during the follow-
up visits every 8 weeks (¬± 7 days) (12 weeks (¬± 7 days) for Cycles ‚â• 6)  until documented 
disease progression, initiation of new anticancer therapy or discontinuation of patient from 
overall study participation (e.g., death, patient's request, lost to follow-up), whichever occurs 
first. Every effort should be made to perform a last tumor assessment before starting a new 
anticancer therapy. Additional unscheduled tumor assessments may be performed as 
clinically indicated at any time. 
Patients last known to be 1) alive and 2) progression-free, are censored at the date of the last 
objective
 disease assessment that verified lack of disease progression (see Appendix 10.4 for 
determi
ning the date in details). In addition, 
ÔÇ∑ Patients with no baseline tumor assessment (including patients with an inadequate 
base
line assessment) within 18 weeks after the randomization date will be censored 
on the randomi
zation date, unless the patient dies within 18 weeks of the 
randomization date, in which case, death will be an event on date of death. 
ÔÇ∑ Patients with no adequate post-baseline tumor assessments within 18 weeks after the 
randomiz
ation date will be censored on the randomization date, unless the patient dies 
within 18 weeks of the randomization date, in which case, death will be an event on 
date of
 death. 
ÔÇ∑ If a new anti-cancer treatment is started prior to progression and death, then 
ce
nsorship is at the date of the last objective disease assessment that verified lack of 
disease progression prior to the new treatment. 
ÔÇ∑ If patients are removed from the study (withdrew the consent, lost to follow up, etc.) 
prior to pro
gression and death, then censorship is at the date of the last objective 
disease assessment that verified lack of disease progression. 
ÔÇ∑ Patients with documentation of progression or death after an unacceptably long 
inte
rval (>2 consecutive assessments) since the last tumor assessment will be 
censored at the time of last objective assessment documenting no progression. 

Protocol A5481059 Statistical Analysis Plan V4 
 
 
Page 20  
Six-month progression-free survival (6m-PF S) is defined as the PFS status (progression free 
and alive, or not) at 6-months. The 6-month PFS rate is summarized as a product limit estimator 
based on the Kaplan-Meier method to account for censored events.  
 
Overall Survival (OS)  is defined as the time from the date of first dose to the date of death 
due to any
 cause.  OS (in months) is calculated as (date of death ‚Äì first dose date +1)/30.4.  
For pa
tients lacking survival data beyond the date of their last follow-up, the OS time will be 
censore
d on the last date they were known to be alive.  Patients lacking survival data beyond 
first dose will have their OS times be censored at first dose.   
Following
 the End of Treatment visit, survival status will be collected in all patients every 
month (¬±7 days) from the last dose of study treatment.  Information on subsequent anticancer 
therapy will also be collected. 
The unacceptably long intervals (>2 consecutive assessments) are defined as following: 1) 
PD occurs during Cycle 4 to 7 or death occurs during Cycle 3 to 6, the unacceptable interval 
is grea
ter than 18 weeks. 2) PD occurs at Cycle 8 or death occurs during Cycle 7, the 
unacceptable interval is greater than 22 weeks. 3) PD occurs at/after Cycle 9 or death occurs 
at/after Cycle 8, the unacceptable interval is greater than 26 weeks.      
 
6.1.2.7. Pharmacokinetics  
Pharmacokinetic parameters of palbociclib and nab-paclitaxel:   
o For palbociclib PK when given with nab-paclitaxel: Multiple Dose (MD) (assuming 
stead
y-state is achieved) - C ss,max, Tss,ma x, AUC ss,ÔÅ¥, Css,trough, and CL/F, as data permit; 
o For total paclitaxel when nab -paclitaxel is given alone and in combination with 
palbociclib: C max, Tmax, AUC last, AUC ‚àû, t1/2, CL, and V z as data permit.   
 
6.1.2.7.1. Palbociclib Pharmacokinetic Assessments 
Plasma PK samples for palbociclib determination will be collected on Day 13 of Cycle 1 at 0 
(pre-dose), 2, 4, 6, 8 and 24 hours post palbociclib dose, and on Cycle 2 Days 1 and 15 (pre-
dose)  as described in Schedule of Activities. Patients must have received at least 7 
consecutive days of palbociclib before PK assessments on Cycle 1 Day 13 and Cycle 2 Day 
15.   
Additional instructions for serial PK sampling on Cycle 1 Day 13 include the following: 
ÔÇ∑ The palbociclib dose that is taken on C1D12 should be at least 20 hours from the time 
the pre
-dose PK sample is drawn on C1D13. Patients should record the time of their 
C1D12 palbociclib dose in the patient diary.  
ÔÇ∑ Patients must not take their palbociclib dose on C1D13 until after the pre-dose PK 
sample is drawn.  Patients must be instructed to bring their palbociclib dose with 
them to the clinic. 

3URWRFRO$ 6WDWLVWLFDO$QDO\VLV3ODQ9


3DJHx%HFDXVHSDWLHQWVPXVWWDN HSDOERFLFOLEZLWKIRRGWKHLQYHVWLJD WRUPXVWSURYLGHWKH
SDWLHQWZLWKDVWUXFWXUHGPHD ORQ&'7KHWRWDOQXWULWLRQDO FRPSRVLWLRQVKRXOGEH
DSSUR[LPDWHO\FDUERK\ GUDWHIDWDQGSURWHLQ7KHFD ORULFLQWDNHSHUIRU
WKHPHDOVKRXOGEHDSSUR[LPDWHO\NFDO7KHPHDOVKRXOG EHHDWHQZLWKLQ
PLQXWHVSULRUWRDGPLQLVWUDWLRQRISD OERFLFOLEDQGWKHSDWLHQW VKRXOGFRQVXPHDWOHDVW
RIWKHPHDOSURYLGHGEHIRUHSDOERFLFOLEGRVLQJ
x3DOERFLFOLEPXVWEHDGPLQLVWHUH GDVFORVHDVSRVVLEOHWRWKHVW DUWRILQIXVLRQRIQDE
SDFOLWD[HO
2WKHU3.VDPSOLQJGD\V&'&'2QWKHGD\VZKHUHWURXJK 3.VDPSOHVDUHGUDZQ
SDWLHQWVPXVWQRWWDNHWKHLU SDOERFLFOLEGRVHXQWLODIWHUWKHS UHGRVH3.VDPSOHLVGUDZQ
2QFHWKHSUHGRVH3.VDPSOH LVGUDZQSDWLHQWVVKRXOGWDNHWKHLU SDOERFLFOLEGRVHZLWKDQ\
IRRGWKHSDWLHQWSUHIHUVD VFORVHDVSRVVLEOHWRWKHVWDUWRI QDESDFOLWD[HOLQIXVLRQ7KH
LQYHVWLJDWRUVKRXOGSODQWRSURYLGHWKH SDWLHQWZLWKDPHDORQ WKHVHGD\V
,QWKHHYHQWQDESDFOLWD[H OLVQRWGRVHGRQ'D\3.VDPSOHV IRUSDOERFLFOLEGHWHUPLQDWLRQ
FDQEHFROOHFWHGRQWKHGD\WKHWKLUGGR VHRIQDESDFOLWD[HOLV DGPLQLVWHUHGDVORQJDVWKHUHLV
QRGRVHLQWHUUXSWLRQUHGXFWLRQRUGHOD\RISDOERFLFOLEGRVLQJ ZLWKLQGD\VRIWKHLQWHQGHG
QDESDFOLWD[HOGRVLQJDQG3 .VDPSOLQJ,QWKHHYHQW3.VDPSOHV FDQQRWEHFROOHFWHGRULV
QRWFROOHFWHGRQ'D\RI&\FOHRUWKHGD\RIWKLUGQDESDF OLWD[HOGRVLQJHYHU\HIIRUW
VKRXOGEHPDGHWRFROOHFWPDNHXSVDPSOHVRQ'D\RI&\FOHR UWKHGD\ZKHQWKHWKLUG
GRVHRIQDESDFOLWD[HOLQ&\FOHRUODWHUF\FOHVLVDGPLQLVW HUHGXVLQJWKHVDPHFULWHULD
7KH'D\KRXU3.VDPSOHVKRXO GEHFROOHFWHGSULRUWRWKH DGPLQLVWUDWLRQRIWKH'D\
SDOERFLFOLEGRVH7KHH[DFWWLP HRIWKHVDPSOHFROOHFWLRQDQG WKHPRVWUHFHQWGRVLQJWLPH
EHIRUHDQGDIWHU3.VDPSOHF ROOHFWLRQZLOOEHUHFRUGHGRQWKH& 5)7KHGDWHRIPLVVLQJGRVH
VKRXOGDOVREHUHFRUGHGLQWKH&5)
'XULQJDOOVWXG\SHULRGVEORRGVDPSOHVP/WRSURYLGHDSSUR [LPDWHO\P/RISODVPDIRU
SKDUPDFRNLQHWLFDQDO\VLVZLOOEHF ROOHFWHGLQWRDSSURSULDWHO\O DEHOHGWXEHVFRQWDLQLQJ
GLSRWDVVLXPHWK\OHQHGLDPL QHWHWUDDFHWLFDFLG.
('7$DWWLPHVVSHFLILHGLQWKH 

7KHDFWXDOWLPHVPD\FKDQJHEXWWKH QXPEHURIVDPSOHVZLOOUHPD LQWKHVDPH$OOHIIRUWV
ZLOOEHPDGHWRREWDLQWKHSKDUPD FRNLQHWLFVDPSOHVDWWKHH[DFW QRPLQDOWLPHUHODWLYHWR
GRVLQJ+RZHYHUVDPSOHVREW DLQHGZLWKLQRIWKHQRPLQDOWL PHHJZLWKLQPLQXWHV
RIDPLQXWHVDPSOHIU RPGRVLQJZLOOQRWEHFDSWXUHGDVDSU RWRFROGHYLDWLRQDVORQJDV
WKHH[DFWWLPHRIWKHVDPSOHFROOHFWLRQLVQRWHGRQWKHVRXUFH GRFXPHQWDQGGDWDFROOHFWLRQ
WRROHJ&5)'&7
6DPSOHVZLOOEHDQDO\]H GXVLQJDYDOLGDWHGDQDO\WLFDOPHWKRGLQ FRPSOLDQFHZLWK3IL]HU
VWDQGDUGRSHUDWLQJSURFHGXUH V$VSDUWRIXQGHUVWDQGLQJWKH3. RIWKHSDOERFLFOLEEORRG
VDPSOHVPD\EHXVHGIRUPHWD EROLWHLGHQWLILFDWLRQDQGRUHYDOXD WLRQRIWKHELRDQDO\WLFDO
PHWKRG 
CCICCI
3URWRFRO$ 6WDWLVWLFDO$QDO\VLV3ODQ9


3DJH6.1.2.7.2.Nab-Paclitaxel Pharmacokinetic Assessments 
3ODVPD3.VDPSOHVIRUWRWDOSDF OLWD[HOGHWHUPLQDWLRQZLOOEHFR OOHFWHGRQ'D\VWR'D\
DQG'D\VWRRI&\FOHDWSUHGRVHHQGRILQIXV LRQDQG
KRXUVSRVWWKHVWDUWRIQDESDFOLWD[ HO,9LQIXVLRQDVGHVFULEHG LQ62$7KHSUHGRVHVDPSOHV
VKRXOGEHFROOHFWHGMXVWEHIRUHWK HVWDUWRIWKHQDESDFOLWD[HO LQIXVLRQ2Q'D\1DE
SDFOLWD[HODQGSDOERFLFOLEVKRXO GEHGRVHGDWDSSUR[LPDWHO\WKH VDPHWLPH7KH3.VDPSOHV
VKRXOGEHGUDZQIURPWKHRSSRVLWHDUPRIWKH,9LQIXVLRQ)RU' D\DQG3.VDPSOHV
WKH3.VDPSOHVZLOORQO\EHFROOHF WHGIRUSDWLHQWVZKRKDYHUHF HLYHGDWOHDVWFRQVHFXWLYH
GD\VRISDOERFLFOLEGRVLQJ)RU SDWLHQWVZKRKDGDSDOERFLFOLE GRVHLQWHUUXSWLRQUHGXFWLRQRU
GHOD\VZLWKLQGD\VRIWKHWKLUGQD ESDFOLWD[HOGRVH3.VDPSO HVFROOHFWLRQFDQEHPDGHXS
LQODWHUF\FOHV,QWKHHYH QWRIQDESDFOLWD[HOLVQRWGRVHGR Q'D\3.VDPSOHVIRUWRWDO
SDFOLWD[HOGHWHUPLQDWLRQ FDQEHFROOHFWHGRQWKHGD\WKHWKLUG QDESDFOLWD[HOGRVHLV
DGPLQLVWHUHGDVORQJDVW KHUHLVQRGRVHLQWHUUXSWLRQUHGXFWLR QRUGHOD\RISDOERFLFOLEGRVLQJ
ZLWKLQGD\VRIWKHLQWHQGHGQDESD FOLWD[HOGRVLQJDQG3.VDPS OLQJ,QWKHHYHQW3.
VDPSOHVFDQQRWEHFROOHFWHG RULVQRWFROOHFWHGRQ'D\RI &\FOHRUWKHGD\RIWKLUG
QDESDFOLWD[HOGRVLQJHYHU\HIIRUWVKRXOGEHPDGHWRFROOHFWP DNHXSVDPSOHVRQ'D\RI
&\FOHRUWKHGD\ZKHQWKHWKLUGGRVHRIQDESDFOLWD[HOLQ&\F OHRUODWHUF\FOHVLV
DGPLQLVWHUHGXVLQJWKHVDPHFULWHULD7KHH[DFWGDWHDQGWLPHR IWKHVDPSOHFROOHFWLRQDQGWKH
H[DFWVWDUWDQGVWRSWLPHRIWKHQD ESDFOLWD[HOLQIXVLRQZLOOE HUHFRUGHGRQWKH &5)7KHGDWH
RIPLVVLQJGRVHVVKRXOGDOVREHU HFRUGHGLQWKH&5)
'XULQJDOOVWXG\SHULRGVEORRGVDPSOHV P/WRSURYLGHDSSUR[LPDWHO\P/RISODVPD
IRUSKDUPDFRNLQHWLFDQDO\VLVZLOO EHFROOHFWHGLQWRDSSURSULDWH O\ODEHOHGWXEHVFRQWDLQLQJ
VRGLXPKHSDULQDWWLPHVVSHFLILHGLQWKH 

7KHDFWXDOWLPHVPD\FKDQJHEXWWKH QXPEHURIVDPSOHVZLOOUHPD LQWKHVDPH$OOHIIRUWV
ZLOOEHPDGHWRREWDLQWKHSKDUPD FRNLQHWLFVDPSOHVDWWKHH[DFW QRPLQDOWLPHUHODWLYHWR
GRVLQJ+RZHYHUVDPSOHVREWD LQHGZLWKLQRIWKHQRPLQDOWL PHHJZLWKLQPLQXWHV
RIDPLQXWHVDPSOHIU RPGRVLQJZLOOQRWEHFDSWXUHGDVDSU RWRFROGHYLDWLRQDVORQJDV
WKHH[DFWWLPHRIWKHVDPSOHFROOHFWLRQLVQRWHGRQWKHVRXUFH GRFXPHQWDQGGDWDFROOHFWLRQ
WRROHJ&5)'&7
$VSDUWRIXQGHUVWDQGLQJWKH3.RIWRW DOSDFOLWD[HOIROORZLQJQ DESDFOLWD[HODGPLQLVWUDWLRQ
EORRGVDPSOHVPD\EHXVHGIRU HYDOXDWLRQRIWKHELRDQDO\WLFDOP HWKRG 

6.1.2.8.Biomarkers  
$QDUFKLYDOWXPRUWLVVXHVDPSOHRUGHQRYRWXPRUELRSV\WLVVXH VLVUHTXLUHGIURPDOO
SDWLHQWVIRUVWXG\SDUWLFLSDWLRQ
6SHFLILFDOO\DQ))3 (WLVVXHEORFNWKDWFRQWDLQVVXIILFLHQWWLV VXHWRJHQHUDWHDWOHDVW
SUHIHUDEO\XQVWDLQHGVOLGHVHDFKZLWKWLVVXHVHFWLRQVWKD WDUHPLFURQVWKLFNVKRXOGEH
FROOHFWHG,IDQ))3(WLVVXHEORFN FDQQRWEHSURYLGHGDWOHDVW SUHIHUDEO\XQEDNHG
JODVVVOLGHVHDFKFRQWDLQLQJDQXQVWDLQHGPLFURQ))3(WLVVXH VHFWLRQLVUHTXLUHG,IDQ
DUFKLYDOWXPRUWLVVXHVDPSOHLVQR WDYDLODEOHDGHQRYRWXPRU ELRSV\VSHFLPHQPXVWEHCCICCI
3URWRFRO$ 6WDWLVWLFDO$QDO\VLV3ODQ9


3DJHREWDLQHGEHIRUHLQYHVWLJDWLRQDOSURGXFWVD UHDGPLQLVWHUHG&\FO H'D\7XPRUWLVVXH
IURPF\WRORJLFVDPSOLQJHJILQHQHHGOHDVSLUDWLRQLQFOXGLQ J))3(FHOOSHOOHWPDWHULDOLV
QRWDGHTXDWHDQGVKRXOGQRWEHVXEPLWWHG6SHFLPHQVZLOOEHVHQ WWRWKHVSRQVRUGHVLJQDWHG
FHQWUDOODERUDWRU\5HVXOWVIUR PWKH5EDQGSH[SUHVVLRQWH VWLQJE\,+&ZLOOEHXVHGIRU
VHQVLWLYLW\DQDO\VHV 




x
x


'HWDLOHGLQIRUPDWLRQDERXWELRPDUNHUVDPSOHFROOHFWLRQSUHSDUD WLRQVWRUDJHODEHOLQJDQG
VKLSPHQWLVLQGLFDWHGLQWKH6WXG\0DQXDO5HIHUWRWKH6FKHGXO HRI$FWLYLWLHVIRUGHWDLOV
SHUWDLQLQJWRVSHFLILFGD\VRIVDPSOHFROOHFWLRQ
7KHVHDQDO\VHVPD\DOVR OHDGWRWKHLGHQWLILFDWLRQRISRWHQWLDO ELRPDUNHUVRIUHVSRQVHWRWKH
FRPELQDWLRQWUHDWPHQWXOWLPDWHO\ OHDGLQJWRWKHGHYHORSPHQWRI DSDWLHQWVHOHFWLRQVWUDWHJ\
IRUIXUWKHUFOLQLFDOLQYHVWLJDWLRQ
Table 6.2 Summary of Biomarker Assessments 
$VVD\ 6RXUFH
SDQG5EVWDWXV $UFKLYDOWXPRUVSHFLPHQDQGRU
GHQRYRWXPRUELRSVLHV
CCI
CCI
CCI
CCI
3URWRFRO$ 6WDWLVWLFDO$QDO\VLV3ODQ9


3DJH6.1.2.8.1.Optional De Novo Tumor Tissue Biopsy for Pharmacodynamic Analys is 
)RUSDWLHQWVZKRFRQVHQW WKHRSWLRQDOGHQRYRWXPRUELRSV\FRO OHFWLRQVKRXOGEHFROOHFWHGDW
6FUHHQLQJDQG(QGRI7UHDWPH QW,IFROOHFWHGWKHVHVSHFLPHQV ZLOOEHSURYLGHGLQDGGLWLRQ
WRWKHDUFKLYDOWXPRUWLVVXHVSHFLPH QWKDWLVUHTXLUHGIRUHOLJ LELOLW\SXUSRVHV7XPRUWLVVXH
IURPF\WRORJLFVDPSOLQJHJILQHQHHGOHDVSLUDWLRQLQFOXGLQ J))3(FHOOSHOOHWPDWHULDOLV
QRWDGHTXDWHDQGVKRXOGQRWEHVXEPLWWHG'HWDLOVIRUKDQGOLQJ RIWKHVHVSHFLPHQVLQFOXGLQJ
SURFHVVLQJVWRUDJHD QGVKLSPHQWZLOOEHSURYLGHGLQWKH6WXG\ 0DQXDO
'HQRYRWXPRUFRUHELRSV\FROOHF WLRQLVVWURQJO\HQFRXUDJHGXQO HVVLWSRVHVDVDIHW\ULVNWR
WKHSDWLHQWLQWKHRSLQLRQRIWKHLQYHVWLJDWRU7KHWXPRUWLV VXHZLOOEHXVHGIRU
SKDUPDFRG\QDPLFDVVHVVPHQW DQGWRIXUWKHUGHWHUPLQHSRVVLEOHPH FKDQLVPVRI
VHQVLWLYLW\UHVLVWDQFHWRVWXG \WUHDWPHQW([DPSOHVRIVXFKEL RPDUNHUVPD\LQFOXGH
SKRVSKR5ES(5.)R[0.LDQG781(/DSRSWRVLVPDUNHUV
 









  
  
 CCI
CCI
CCI
CCICCI
3URWRFRO$ 6WDWLVWLFDO$QDO\VLV3ODQ9


3DJHCCI
3URWRFRO$ 6WDWLVWLFDO$QDO\VLV3ODQ9


3DJHCCI
Protocol A5481059 Statistical Analysis Plan V4 
 
 
Page 27 6.2.2. Stratification Factors  
Not applicable. 
7. HANDLING OF MISSING VALUES 
7.1. M
issing Dates 
In compliance with Pfizer standards, if the day of the month is missing for any date used in a 
calculation, the 1st of the month will be used to replace the missing date unless the 
calculation results in a negative time duration (e.g., date of onset cannot be prior to day one 
date).  
In this case, the date resulting in 1 day duration will be used. If the day of the month 
and the month is mi
ssing for any date used in a calculation, January 1 will be used to replace 
the missing date. 
Missing dates for adverse events will be imputed based on the similar principle. 
ÔÇ∑ For the start date, if the day of the month is missing, the 1st day of the month will be 
used to replac
e the missing date. If both day and month are missing, January 1 of the 
non-missing year will be used to replace the missing date. If the first dose date is later 
than this imputed da
te, then impute the start date again to the first dose date. 
ÔÇ∑ For the stop date, if the day of the month is missing, the last day of the month will be 
used to replace the missing date. If both day and month are missing, December 31 of 
the non-missing year will be used to replace the missing date. 
 
If the start date is missing for an AE, the AE is considered to be treatment emergent unless 
the collection date is prior to the treatment start date. 
 
7.2. Missing Tumor Assessments 
If baseline tumor assessment is inadequate the patient cannot be assessed for response. 
Inadequate baseline assessment may include  
ÔÇ∑ Not all required baseline assessments were done 
ÔÇ∑ Asse
ssments were done outside the required window  
ÔÇ∑ Measurements were not provided for one or more target lesions 
ÔÇ∑ One or more lesions designated as target were not measurable. 
 
If mea
surements for one or more target lesions are missing for an evaluation and disease does 
not qualify as progression (or symptomatic deterioration if applicable), the objective status 
for that evaluation is Indeterminate. 
If non-target disease was not assessed, then objective status cannot be a CR even if all target 
disease has disappeared.  Otherwise, missing non-target disease assessments do not 
necessarily affect response determination.  Such cases will be reviewed carefully. 

3URWRFRO$ 6WDWLVWLFDO$QDO\VLV3ODQ9


3DJH,IDOHVLRQPHDVXUHPHQWLVPLVVLQJEHFDXVHLWLVGRFXPHQWHGDV WRRVPDOOWRPHDVXUHWKH
YDOXHPPZLOOEHDVVLJQHGDQGREMHF WLYHVWDWXVFDOFXODWHGDFF RUGLQJO\
,QWKHDVVHVVPHQWRI25SDWLHQWVZKRGRQRWKDYHRQVWXG\UDGL RJUDSKLFWXPRUUH
HYDOXDWLRQVZLOOEHFRXQWH GDVQRQUHVSRQGHUV

7.3.Missing Data in PFS Derivation 
3)6FDQQRWEHDVVHVVHGLQSDWLHQWVZLWKLQDGH TXDWHEDVHOLQHWXP RUDVVHVVPHQW3)6FDQQRW
EHDVVHVVHGLQSDWLHQWVZKRKDYHQRRQ VWXG\DVVHVVPHQWVXQOHVV GHDWKRFFXUVSULRUWRWKH
ILUVWSODQQHGDVVHVVPHQWWLPH
,IDVXEVWDQWLDOQXPEHURISDWL HQWVKDYHTXHVWLRQD EOHIDLOXUHR UFHQVRUVKLSGDWHVIRUHLWKHU
3)6GHILQLWLRQVXFKDVSURJUH VVLRQRUGHDWKQRWGRFXPHQWHGXQW LODIWHUPXOWLSOHPLVVLQJ
DVVHVVPHQWVVFHQDULRVVXFKDVEHVWFDVH IDLOXUHDWWLPHRIGR FXPHQWDWLRQDQGZRUVWFDVH
SURJUHVVLRQDWHDUOLHVWSRVVL EOHSODQQHGDVVHVVPHQWGDWHZLOO EHLQYHVWLJDWHG
)RUWLPHWRHYHQWHQGSRLQWVQRYD OXHVZLOOEHLPSXWHGIRUPLVV LQJGDWDDQGQRQHYHQW
REVHUYDWLRQVZLOOEHFHQVRUHGDVGHILQHGLQ6HFWLRQ
,IFRQYHQWLRQVUHVXOWLQDQHJDWLYH
GXUDWLRQGXUDWLRQVZLOOEHUHVHWWRGD\ 

7.4.Missing QTc Data 
)RU47FDQDO\VLVQRYDOXH VZLOOEHLPSXWHGIRUPLVVLQJGDWDH[ FHSWIRUDYHUDJLQJRI
WULSOLFDWHPHDVXUHPHQWV,IRQH RUWZRRIWKHWULSOLFDWHPHDVXU HPHQWVIRUDQ(&*SDUDPHWHU
DUHPLVVHGWKHDYHUDJHR IWKHUHPDLQLQJWZRPHDVXUHPHQWVRUWK HVLQJOHPHDVXUHPHQWFDQ
EHXVHGLQWKHDQDO\VHV,IDOO WULSOLFDWHPHDVXUHPHQWVDUHPLV VLQJDWDWLPHSRLQWIRUDQ(&*
SDUDPHWHUQRYDOXHVZLOO EHLPSXWHGIRUWKLVWLPHSRLQWDQGQR DQDO\VHVUHODWHGWRWKLVWLPH
SRLQWZLOOEHSHUIRUPHG,IWKHWU LSOLFDWHLVQRWJRRGEHFDXVH RIDQDUWLIDFWWKHQLIWKH
WULSOLFDWHLVUHSHDWHGZLWKLQDERXW rPLQXWHVFDQEHXVHGD WWKDWQRPLQDOWLPH3DWLHQWV
ZKRKDYHGDWDRQRWKHUGD\VR UXQVFKHGXOHG(&*VEXWQRWDWWKH WLPHVRIWKHIRUPDO
VWDWLVWLFDODQDO\VLVZLOOEHLQFOXGHGLQW KHFDWHJRULFDOWDEOHV EXWQRWWKHVWDWLVWLFDODQDO\VHV
7.6.Missing PK Samples 
&RQFHQWUDWLRQVEHORZWKHOLPLWRITXDQWLILFDWLRQ 
)RUDOOFDOFXODWLRQVILJXUHVDQGHVWLPDWLRQRILQGLYLGXDOSKDU PDFRNLQHWLFSDUDPHWHUVDOO
FRQFHQWUDWLRQVDVVD\HGDVEHORZWKHOHYHORITXDQWLILFDWLRQ%/ 4ZLOOEHVHWWR]HUR,QORJ
OLQHDUSORWVWKHVHYDOXHVZRXOGQRWEHUHSUHVHQWHG7KH%/4YDO XHVZLOOEHH[FOXGHGIURP
FDOFXODWLRQVRIJHRPHWULFPHDQVDQGWKHLUFRQILGHQFHLQWHUYDOV $VWDWHPHQWVLPLODUWR¬≥$OOCCI
Protocol A5481059 Statistical Analysis Plan V4 
 
 
Page 29 values reported as BLQ have been replaced with zero‚Äù should be included as a footnote to the 
appropriate tables and figures.  
Deviations, missing concentrations and anomalous values  
In summary tables and plots of median profiles, statistics will be calculated. Concentrations will 
be set to missing if one of the following cases is true:  
ÔÇ∑ A concentration has been reported as ND (i.e., not done) or NS (i.e., no sample),  
ÔÇ∑ A deviation in sampling time is of sufficient concern or a concentration has been 
flagge
d as anomalous by the pharmacokineticist.  
 
Note that summary statistics will not be presented at a particular time point if more than 50% of 
the data are missing. For analysis of pharmacokinetic concentrations, no values will be imputed 
for missing data.  
Pharmacokinetic parameters  
Actual PK sampling times will be used in the derivation of PK parameters (and where possible 
the actual dosing information). If a PK parameter cannot be derived from a patient‚Äôs 
concentration data, the parameter will be coded as NC (i.e., not calculated). (Note that NC values 
will not be generated beyond the day that a patient discontinues).  
In summary tables, statistics will be calculated by setting NC values to missing; and statistics will 
not be presented for a particular treatment if more than 50% of the data are NC. For statistical 
analyses (i.e., analysis of variance), PK parameters coded as NC will also be set to missing.  
If an individual patient has a known biased estimate of a PK parameter (due for example to an 
unexpec
ted event such as vomiting before all the drug is absorbed in the body), this will be 
footnoted in summary tables and will not be included in the calculation of summary statistics or 
statistical analyses.  
7.7. Missing/Duplicate Biomarker Data 
No values will be imputed for missing data.  If there is duplicate biomarker data for an 
assessment that is not expected (e.g., the same sample was sent twice to the assay laboratory, 
or the laboratory reported two assessments for the same sample), the following will occur.  
Numerical biomarker values will be averaged for reporting purposes and the average will be 
included in the listing of biomarker data along with the original data.  Non-numerical data 
(e.
g., mutations present) will be reviewed by the clinical subteam to determine which data 
will be included in the analyses, if any; that record will have a flag added to show it was used 
for analysis purposes. 

Protocol A5481059 Statistical Analysis Plan V4 
 
 
Page 30 8. STATISTICAL METHODOLOGY AND STATISTICAL ANAL YSES 
8.1. Statistical Methods  
8.1.1. mTPI Method - Dose Escalation/De-Escalation 
The rules f
or dose escalation/de-escalation will follow a modified toxicity probability 
interval (mTPI) method. The mTPI method relies upon a statistical probability algorithm 
which is calculated using all patients treated at the same dose level. Upon completion of a 
group (i.e., all patients in that cohort are evaluable for DLT), a decision to escalate, de-
escalate, or stay (i.e., enroll an additional group at the current dose level) will be made.   
Many alternative designs have been proposed to the standard 3+3 design for Phase 1 dose 
esca
lation studies that improve its accuracy, efficiency and statistical validity.  
The modified toxicity probability interval (mTPI) design uses a Bayesian statistics 
framework and a beta/binomial hierarchical model to compute the posterior probability of 
three dosing intervals that reflect the relative difference between the toxicity rate of each 
dose level to the target rate (pT = 0.28). If the toxicity rate of the currently used dose level is 
far smaller than pT, the mTPI will recommend escalating the dose level; if it is close to target 
probability (pT), the mTPI will recommend continuing at the current dose; if it is far greater 
than pT, the mTPI will recommend de-escalating the dose level. These rules are conceptually 
simila
r to those used by the 3+3 design, except the decisions of an mTPI design are based on 
posterior probabilities calculated under a coherent probability model.  
Being a model-based design, mTPI automatically and appropriately tailors dose-escalation 
and de-escalation decisions for different studies with different toxicity parameters. More 
importantly, all the dose-escalation decisions for a given study can be pre-calculated under 
the mTPI design and presented in a two-way table below (Table 8.1). Thus, compared to 
other adva
nced model-based designs published in the literature, the mTPI design is 
logistically less complicated and easier to implement.  
Table 8.1 Number of Patients with DLT for Dose Escalation Decisions at a Dose Level 
  Total Number of DLT Evaluable Patients  
 2 3 4 5 6 7 8 9 10 
Escalate 0 0 0 0 0-1 0-1 0-1 0-2 0-2 
Stay 1 1 1 1-2 2 2 2  3 
De-Escalate & revisit 
allowed  2 2   3 3-4 3-4 4-5 
De-Escalate &  revisit not 
allowed  2 3 3-4 3-4 3-5 4-5 5 5 6 
 
Decision rules are based on calculating unit probability mass (UPM) of three dosing intervals 
corresponding to under, proper, and overdosing in terms of toxicity. Specifically, the 
underdosing interval is defined as (0; pT-e 1), the overdosing interval (pT+e 2), and the proper-
dosing interval (pT- e 1, pT+ e 2), where e 1 and e2 are small fractions. Based on the safety 

Protocol A5481059 Statistical Analysis Plan V4 
 
 
Page 31 profile of palbociclib as a single-agent in Study A5481001, e 1 is selected as 0.03, and e 2 is 
selected as 0.045. Therefore, the target interval for the DLT rate is (0.25, 0.325). 
The three dosing intervals are associated with three different dose-escalation decisions. The 
underdosing interval corresponds to a dose escalation (E), overdosing corresponds to a dose 
de-escalation (D), and proper-dosing corresponds to remaining at the current dose (R). Given 
a dosing interval and a probability distribution, the unit probability mass (UPM) of that 
dosing interval is defined as the probability of a patient belonging to that dosing interval 
divided b
y the length of the dosing interval. The mTPI design calculates the UPMs for the 
three dosing intervals, and the one with the largest UPM informs the corresponding dose-
finding decision, which is the dose level to be used for future patients. For example, if the 
underdosing interval has the largest UPM, the decision will be to escalate, and the next 
cohort of patients will be treated at the next higher dose level. Ji et al. (2010) have 
demonstrated that the decision based on UPM is optimal in that it minimizes a posterior 
expected loss (i.e. minimizes the chance of making a wrong dosing decision).  
The dose-finding portion of the study is terminated when either approximately 30 DLT 
evaluable patients have been enrolled or when at least 9 evaluable patients have been treated 
at the highest dose with DLT rate <33 %, whichever comes first. 
8.1.2. Estimating the Maximum Tolerated Dose  
As previously described, the estimated MTD is the highest tested dose level with DLT rate 
<0.33 in at least 9 DLT evaluable patients. It is assumed that higher doses of either 
palbociclib or nab-paclitaxel result  in higher toxicity rates.  But, due to the relatively low 
number of patients that may be potentially allocated to any dose combination, this 
assumption may be violated.  
For example, at the end of the study, the dose combination palbociclib 100 mg and nab-
paclitaxel  125 mg/m2 may have a higher proportion of observed toxicities than, say, 
palbocicli
b 125 mg , nab-paclitaxel 125 mg /m2, and this variability may be simply related to 
small cohort size alone.  To overcome this potential problem, a bivariate isotonic regression 
is used to smooth the resulting toxicity surface to a monotonically increasing one.  The 
determination of the MTD contour i s accomplished using the Dykstra -Roberston algorithm. 
Once a monotonically increasing toxicity surface is obtained (either observed or smoothed 
according to the bivariate isotonic regression algorithm), the MTD combinations closest to 
the targeted DLT rate  of 0.28 but still <0.33 are calculated.  Clinical judgment will be 
exercised in taking forward combinations to the MTD expansion cohort(s) in case no clear 
choice exists between more than 1 competing MTD combination s. While the limited sample 
size may res ult in up to 2 dose combinations of equal potential anti -tumor activity, under the 
circumstances of this study, it is possible that 2 MTD expansion cohorts will be explored. 
This decision will be based upon the combination of data related to safety, PK, PD , anti-
tumor activity, and clinical judgment of the investigators and the sponsor.  

Protocol A5481059 Statistical Analysis Plan V4 
 
 
Page 32 8.1.3. Analyses for Time- to-Event Data 
Time-to-event endpoints will be summarized using the Kaplan-Meier method and displayed 
graphically when appropriate.  Median event times and 2-sided 95% confidence interval (CI) 
for the media
n based on Brookmey er-Crowley method will be provided.   
 
The X-year survival probability will be estimated using the Kaplan-Meier method and a 2-
sided 95% CI  
for the log [-log(X-year survival probability )] will be calculated using a normal 
approxim
ation and then back transformed to give a confidence interval for the X-year 
survival probability itself. 
 
8.1.4. Analyses 
of Binary Data 
Binary e
ndpoints will be summarized by percentage rates along with the corresponding exact 2-
sided 95% CI s using the exact method based on Clopper-Pearson method.  
 
8.1.5. Analyses of
 Continuous Data 
Continuous endpoints will be summarized by descriptive statistics, including the mean, standard 
deviation, median, minimum, and maximum values. Descriptive statistics for PK parameters 
and biomarkers will include %CV. 
 
8.1.6. Analyses for Categorical Data  
The number and percentage of patients in each category will be provided for categorical 
variables.   
8.1.7. Analyses for QTc Data  
 
8.1.7.1. Der
ived Analysis Variables 
All ECGs will be recorded in triplicate i.e. three ECGs taken 2 minutes apart. ECG 
assessments reported by the site will include the following parameters: 
 
ECG Parameter  Units Abbreviation  
QTc, Fridericia‚Äôs correction  msec QTcF 
QTc, Bazett‚Äôs correction  msec QTcB 
QT Interval  msec QT 
Heart Rate  bpm HR 
PR Interval  msec PR 
RR Interval  msec RR 
QRS Complex  msec QRS 
 
 
Averaging of triplicate measurements:  
After the above variables have been derived within each patient and scheduled time-point, 
each ECG parameter (including QTcF, QTcB, QT, HR, PR, RR, QRS) should each be 

Protocol A5481059 Statistical Analysis Plan V4 
 
 
Page 33 averaged as follows:  (1st measurement + 2nd measurement + 3rd measurement) / 3.  All 
summar
y statistics, analyses and figures will be based on the triplicate averaged data. 
 
8.1.7.2. Assessment of QT Correction Methods   
This assessment will utilize only Screening and Day 0 triplicate averaged data (‚ÄúStudy drug-
free
‚Äù ECG data). 
The relationship between QT/QTc and RR and the adequacy of each of the 3 QT correction 
methods will be assessed by the following scatterplots (see Figure 1): 
ÔÇ∑ QT, QTcF, and QT cB vs. RR  
Interpretation of the scatterplots should give the following information: 
ÔÇ∑ Variability of the QT/QTc relative to changing RR 
ÔÇ∑ S
lope or lack of slope and pattern to assess adequacy of QT correction method 
ÔÇ∑ Appa
rent patterns in the data 
Figu
re 8.1. A Sample scatterplot of relationship between QT/QTc and RR  
 
 
 
8.1.7.3. Change
 from Baseline Definition 
The change from baseline calculations for ECG measurements (abbreviated as ‚Äúchange‚Äù) is 
derived from the triplicate averaged measurements.  The baseline ECG assessment is defined 
as the triplicate ECG assessment taken pre-dose on Cycle 1 Day 1, or the most recent 
triplicate ECG assessment reported prior to the first administration of study drug.  Change 
from baseline is defined as a patient‚Äôs parameter value at a particular time-point minus the 
appropriately matched baseline value (value - baseline value). Change from baseline 
calcula
tions should only use post-dose ECG measurements. 

Protocol A5481059 Statistical Analysis Plan V4 
 
 
Page 34 8.1.7.4. Outlier Analysis 
QT/QTc outlier values will be summarized and tabulated by the following CTCAE grade 
v.4.03.  
 
Grade 1 2 3 4 5 
Prolonged 
QTc 
interval QTc  450 ‚Äì 
480 msec QTc 481 ‚Äì 
500 msec  QTc ÔÇ≥501 
msec on at 
least two 
separate 
ECGs QTc ÔÇ≥501 or >60 msec 
change from baseline 
and Torsade de pointes 
or polymorphic 
ventricular tachycardia 
or signs/symptoms of 
serious arrhythmia  Death 
 
The change from baseline will summarize occurrences of shift by ÔÇ≥ 1 grade by CTC. 
Individua
l QT and QTc values ÔÇ≥501 msec from each ECG within a triplicate will be flagged 
in data listings. 
In addition, the maximum QTc value for each patient can be categorized and summarized in 
the following cut-offs.  All post dose QTc interval data should be used in determining the 
maximum for
 a patient, including all scheduled and unscheduled ECG‚Äôs.  
 Absolute QTc interval 
prolongation  
QTc < 450 msec 
450 msec ‚â§ QTc ‚â§ 480 msec 
481 msec ‚â§ QTc ‚â§ 500 msec 
QTc ÔÇ≥501 msec 
 
The maximum increase from baseline QTc value for each patient by treatment will be 
categorized and summarized as well.  For reporting the maximum increase QTc value the 
following categories: <30 msec, 30-59 msec and ‚â•60 msec will be used. 
8.2. Statistical Analyses  
All safety and efficacy analyses will be conducted on safety analysis set. Efficacy analyses 
will also be c
onducted on Per Protocol Analysis Set Evaluable for Anti-tumor Activities. All 
anal
yses will be performed by using SAS¬Æ Version 9.4 or higher.  
The ana
lyses of endpoints dependent on disease assessments (PFS, OR, and DR) will be 
based on investi
gator assessments of disease response and progression.  

Protocol A5481059 Statistical Analysis Plan V4 
 
 
Page 35 8.2.1. Analysis of Primary Endpoint (DLT) 
Dose L
imiting Toxicity (DLT) is the primary endpoint of the dose escalation component of 
the study.  The
 occurrence of DLTs observed in the dosing cohorts is used to estimate the 
MTD(s) as described in the protocol.  Adverse Events constituting DLTs will be listed per 
dose level wit
h the following information. 
ÔÇ∑ Patient ID.  
ÔÇ∑ Dose and Date at which DLT occurred.  
ÔÇ∑ Time from treatment start to onset of DLT.  
ÔÇ∑ Time to resolution of DLT to Grade 1 or baseline.  
ÔÇ∑ Dose interruption (yes, no).  
ÔÇ∑ Time to resumption of treatment.  
ÔÇ∑ DLT term.  
ÔÇ∑ Action(s) taken due to DLT (stopped temporarily, permanently discontinued, no action 
taken, etc).  
 
8.2.2. Analysis of Secondary Safety Endpoints 
8.2.2.1. Adverse Events 
All patients treated with at least one dose of study treatment (i.e. palbociclib or nab -
paclitaxel) will be included in all the safety analyses.  
Adverse 
events will be classified using the medical dictionary for regulatory activities 
(MedDRA) classification system.  The severity of the toxicities will be graded according to 
the NCI CTCAE v.4.03 whenever possible ( http://evs.nc i.nih.gov/ftp1/CTCAE/About.html ). 
It should be re
cognized that most studies are not designed to reliably demonstrate a causal 
relationship between the use of a pharmaceutical product and an adverse event or a group of 
adverse events. Except for select ed events in unique situations, studies do not employ formal 
adjudication procedures for the purpose of event classification. As such, saf
ety analysis is 
generally considered as an exploratory analysis and its purpose is to generate hypotheses for 
further investigation.  
Adverse events will be summarized by treatment and by the frequency of patients 
experiencing treatment emergent adverse events corresponding to body systems and 
MedDRA preferred term.  Adverse events will be graded by worst NCI CTCAE v.4.03 grade. 
Adverse 
events will be summarized by cycle and by relatedness to trial treatment. Detailed 
information collected for each AE will include a description of the event, duration, whether 
the AE was serious, intensity, relationship to study drug, action taken, and clinical outcome. 
Emphasis in the analysis will be placed on AEs classified as treatment emergent, those with 
initial onset or increasing in severity after the first dose of investigational product.  The 
number and percentage of patients who experienced any AE, serious AE (SAE), treatment 
related AE, and treatment related SAE will be summarized according to worst toxicity 
grades.  The summaries will present AEs both on the entire study period and by cycle (Cycle 
1 and cycles beyond 1).  

Protocol A5481059 Statistical Analysis Plan V4 
 
 
Page 36 Adverse events leading to death or discontinuation of trial treatment, events classified as NCI 
CTCAE v.4.03 Grade 3 or higher, trial drug related events, and serious adverse events will be 
conside
red with special attention. 
The percentage of patients with an event will be calculated using the number of patients in 
the safety analysis set as the denominator. The denominator for summary tables for each 
laboratory parameter will be all patients in the safety analysis set with at least one evaluable 
cyc
le for that parameter. 
The following summaries of treatment emergent adverse events will also be provided: 
ÔÇ∑ Discontinuations Due to Adverse Events including causality: all cause, treatment 
relate
d, including relationship to specific study treatment of palbociclib and/or nab -
paclitaxel. 
ÔÇ∑ Temporary Discontinuations or Dose Reductions Due to Adverse Events including 
ca
usality and relationship to specific study treatment of palbociclib and/or n ab-
paclitaxel. 
ÔÇ∑ Treatment-Emergent Adverse Events (All Causality, and Treatment Related) 
including the numbe
r of patients evaluable for adverse events, total number of 
adverse events (counting each unique preferred term across all patients), number of 
patients with serious adverse events, number of patients with Grades 3 and 4 adverse 
events, number of patients with Grade 5 adverse events, and number with dose 
reductions or temporary discontinuations due to adverse events 
ÔÇ∑ Treatment-Emergent Adverse Events by MedDRA System Organ Class, Preferred 
Term and Maximum NCI CTCAE v.4.03 Grade (All Causality, and Treatment 
related) 
ÔÇ∑ Treatment-Emergent Adverse Events by MedDRA Preferred Term sorted by 
Desc
ending Order of AE Frequency (All Causality, and Treatment related) 
ÔÇ∑ Treatment-Emergent Adverse Events by Preferred Term ‚Äì  Grade 3/4/5 events with 
number of patients experienced Grade 3-5 AEs and total number of Grade 3-5 AEs, 
sorted by Descending Order of AE Frequency (All Causality, and Treatment 
Related).). 
A summar
y of Serious Adverse Events and listing of deaths reported as serious adverse 
events will be provided. 
8.2.2.2. Laboratory abnormalities 
Hematologic, chemistry and urinalysis laboratory data will be summarized by cycle. The 
hematologic and chemistry laboratory results will be graded according to the NCI CTCAE 
v.4.03 severity grade. The number and percentage of patients who experienced laboratory 
test abnormalities will be summarized according to worst toxicity grade observed for each 
lab assay.  The analyses will summarize laboratory tests both on the entire study period and 

Protocol A5481059 Statistical Analysis Plan V4 
 
 
Page 37 by cycle (Cycle 1 and cycles beyond 1).  Shift tables will be provided to examine the 
distribution of laboratory toxicities. 
For laboratory tests without CTCAE grade definitions, results will be categorized as normal, 
abnormal or not done . 
For CA19-9, results will be summarized in patients count (n) and percentage under the un-
mutuall
y exclusive categories as Maximum %Reduction from baseline ‚â•20%, ‚â•50%, ‚â•70%,  
and ‚â•90%. Reduction from baseline at Week 8 ‚â•20%, >50%,  and ‚â•70%‚Äò , respectively.    
8.2.3. ECG
 Analyses 
The ana
lysis of ECG results will be based on patients in the safety analysis set with baseline 
and on-treatment ECG data.  Baseline is defined as Cycle 1 Day -2.   
ECG measurements (
an average of the triplicate measurements) will be used for the 
statistical analysis and all data presentations.  Any data obtained from ECGs repeated for 
safety reasons after the nominal ti me-points will not be averaged along with the preceding 
triplicates.  Interval measurements from repeated ECGs will be included in the outlier 
analysis (categorical analysis) as individual values obtained at unscheduled time points. 
QT intervals will be corrected for heart rate (QTc) using standard correction factors [i.e. 
Fridericia‚Äôs (default correction), Bazett‚Äôs, and possibly a study specific factor, as 
appropriate].  Data will be summarized and listed for QT, HR, response rate (RR) , PR, QRS, 
QTc (QT
cF, QTcB), and dose.  Individual QT (all evaluated corrections) intervals will be 
listed by
 time and dose.  The most appropriate correction factor will be selected and used for 
the following analyses of central tendency and outliers and used for the study conclusions.  
Descriptive statistics (n, mean, median, standard deviation, minimum, and maximum) will be 
used to summarize the absolute corrected QT interval and changes from baseline in corrected 
QT after treatment by dose and time point.  For each patient, the maximum change from 
baseline will be calculated as well as the maximum post-baseline interval across time points.  
Categorical analysis will be conducted for the maximum change from baseline in corrected 
QT and the maximum post-baseline QT interval.  
Shift tables will be provided for baseline vs worst on treatment corrected QT (one or more 
correction method will be used) using maximum CTCAE Grade.  Shift tables will also be 
provided for ECG abnormality at baseline vs. on treatment (yes, no, not done: (n, %)). 
Patients experiencing clinically-relevant morphological ECG changes will be summarized 
(including frequency and percentage). 
The effect of drug concentrations on corrected QT change from baseline will be explored 
graphically. Additional concentration-corrected QT analyses may be performed. Data may be 
pooled with other
 study results and/or explored further with PK/PD models.  
For all patients in the safety analysis set, categorical analysis of the QTcF/QTcB data will be 
conducted and summarized as fo llows:  

Protocol A5481059 Statistical Analysis Plan V4 
 
 
Page 38 ÔÇ∑ QT/QTc outlier values will be summarized and tabulated by the following CTCAE grade 
v.4.03 according to Section 8.1.7.5.  
ÔÇ∑ The change from baseline will s ummarize occurrences of shift by ÔÇ≥ 1 grade by CTC.  
ÔÇ∑  Individual QT and QTc values ÔÇ≥501 msec from each ECG within a triplicate will be 
flagged in data listings.  
ÔÇ∑ The number of and percentage patients with maximum post -dose QTcF/QTcB  
(<450, 450 -480, 481-500, and ‚â•501  ms), including all scheduled and unscheduled ECG‚Äôs.   
ÔÇ∑ The number and percentage of patients with maximum increase from baseline in 
QTcF/QTcB (<30, 30 - 60, and > 60 ms), including all scheduled and unscheduled ECG‚Äôs.   
ÔÇ∑ PR changes from baseline ‚â• 50% if absolute baseline value was < 200 ms, and ‚â• 25% if 
absolute baseline value was > 200 ms .  
ÔÇ∑ QRS changes from baseline ‚â• 50% if absolute baseline value was < 100 ms, and ‚â• 25% if 
absolute baseline value was > 100 ms.  
ÔÇ∑ The number and percentage of individuals with abnormal ECG findings . 
 
8.2.4. Analyses of Efficacy Endpoints 
The number a
nd proportion of patients achieving objective response (CR or PR) will be 
summariz
ed in the Per Protocol Analysis Set Evaluable for Anti-tumor Activities along with 
the corr
esponding exact 2-sided 95% CI .   
PF
S based on the assessment of investigator will be summarized in the safety analysis set 
using the Ka
plan-Meier method and displayed graphically where appropriate. The median 
event t
ime and corresponding 2-sided 95% CI for the median will be provided for PFS.   
DR will be summa
rized using the Kaplan-Meier methods and displayed graphically where 
appropriate.  DR will be calculated for the subgroup of patients with objective tumor 
response. The median event time and 2-sided 95% CI for the median will be provided.  
Six
-month progression-free survival (6m-PFS) rate will be summarized as a product limit 
estimator based on the Kaplan-Meier method to account for censored events, together with the 
corresponding 2-sided 95% CI. The 2-sided 95% CI for the log[-log(6-month PFS probability)] 
will be calculated using normal approximation and then back transformed to give the CI for the 
6-month PFS rate itself. Analysis result will be included in the table for the PFS analysis.  
Pat
ients will be followed and have tumor assessments performed every 8/12 weeks until disease 
progression or death, patient refusal, start of another anti-cancer treatment, or until 1-year from 
C1D1 of last enrolled patient, whichever occurs first.  
Tumor Response will be presented in the form of patient data listings that include, but are not 
limited to, received (maximum) dose, overall tumor response at each visit, and best overall 
response. In addition, progression date, death date, date of first response and last tumor 
assessment date, dates of first dose and last dose will be listed, together with DR and PFS.  
OS will be summarized in the safety analysis set using the Kaplan-Meier methods and 
displayed graphically where appropriate.  The median event time and 2-sided 95% CI for the 
median will be
 provided.  

Protocol A5481059 Statistical Analysis Plan V4 
 
 
Page 39 The 6-months, 1-year and 2-year survival probabiliti es will be provided with their 95% CIs. 
 
The Clinical Benefit Response (CBR) rate is defined as the percentage of patients with CBR. 
The CB
R rate will be summarized in the Per Protocol Analysis Set Evaluable for Anti-tumor 
Activities along with the corresponding exact 2-sided 95% CI.  
 
8.2.5. Stand
ard Analyses  
Descriptive statistics will be used to summarize study conduct and patient disposition, 
baseline characteristics, and treatment administration/compliance.   
 
ÔÇ∑ Study Conduct and Patient Disposition  - a n accounting of the study patients will be 
tabulated including
 treated, accrual by study center, assessed for AEs, laboratory data, 
biomarke
rs, PK, and QTc, etc.  Patients not meeting the eligibility criteria will be 
identified.  Patients not completing the study will be listed along with the reason for their 
premature discontinuation.  Reasons for premature discontinuation will be summarized.   
ÔÇ∑ Baseline Characteristics  - patient characteristics such as patient age, height, weight, 
gend
er, race, ethnicity, Karnofsky performance status,  Ca19Ca19-9, primary diagnosis, 
prior thera
py (radiotherapy, surgery, systemic therapy), baseline disease site, prior 
medication, medical history, and signs and symptoms at study entry will be summarized 
in frequency tables, and descriptive statistics will be provided for quantitative variables.  
ÔÇ∑ Treatment Administration and Compliance   
ÔÇ∑ Extent of Treatment 
The e
xtent of treatment will be summarized as follows:  
ÔÇ∑ The number and % of patients on treatment and off for each reason 
ÔÇ∑ Tr
eatment assigned vs. actual received  
ÔÇ∑ The
 number and percent of patients beginning 1, 2, 3, 4, 5+ cycles of either study 
drug
  
ÔÇ∑ The number of cycles started (median, minimum, maximum) will be reported 
(overall and by study treatment).    
ÔÇ∑ Duration of treatment (weeks) (overall and by study treatment) 
ÔÇ∑ Cumulative dose and relative dose intensity (see Appendix 10.7  for details) 
(overall and by cycle; by study treatment).).  
 
ÔÇ∑ Treatment Delays and Dose Modifications 
Tre
atment delays and dose modifications of study treatments will be summarized as 
follows including number and percent (see Appendix 10.7 for details): 
 
ÔÇ∑ The number of patients with at least one palbociclib or nab-paclitaxel dose reduction and 
the number of pa
tients with at least one palbociclib or nab -paclitaxel dose omission at 
any
 time during drug administration will be reported. 

Protocol A5481059 Statistical Analysis Plan V4 
 
 
Page 40 ÔÇ∑ The number of patients with at least one palbociclib or nab-paclitaxel dose 
reducti
on due to an adverse event will be reported. 
ÔÇ∑ The number of patients with at least one palbociclib or nab-paclitaxel dose delay 
(i.e. start of f
ollowing cycle is delayed) and percentage due to each reason for the 
delay will be reported  
 
ÔÇ∑ Concomitant medications and Non-drug treatments  
 
Conc
omitant and non-drug treatments refer to all drug and non-drug treatments taken 
while on active treatment (during the effective duration of study treatment), whether 
or not they are recorded at baseline (i.e. have stop day greater than or equal to day 1 
relative to first dose of study drug). Concomitant medication will be summarized in 
freque
ncy tables by treatment. 
 
ÔÇ∑ Follow-Up Therapy  
Foll
ow-up cancer therapy will be summarized by treatment as patients with number 
of regimens (0, 1, 2, ÔÇ≥3), and patients with particular agents. 
 
8.2.6. Analyses of Pharmacokinetic and Pharmacodynamic  
8.2.6.1. Palb
ociclib 
PK samples for palbociclib determination will be collected on Day 13 of Cycle 1 when 
palbociclib is given in combination with nab-paclitaxel for all patients at all dose levels 
studied.  P
lasma pharmacokinetic parameters including maximum plasma concentration at 
steady state ( Css,max), time for Css,max (Tss,max), trough plasma concentration at steady state 
(Css,tro
ugh), area under the plasma concentration -time curve for dosing interval AUCss,œÑ), and 
apparent clearance (CL/F ) for palbociclib will  be esti mated using non -compartmental  
analysis. The effect of nab -paclitaxel  on steady -state palbocic lib exposure will be evaluated 
by comparing palbociclib PK parameters, including C max and AUC œÑ obtained on Day 13 of 
Cyc
le 1 with historical data.  
 
8.2.6.2. Nab-Paclitaxel 
PK samples for total paclitaxel determination will be collected on Days -2 to 1 when nab-
pacli
taxelis given alone and on Days 13-15 when nab-paclitaxel is given in combination with 
multip
le doses of palbociclib.  Plasma PK parameters in cluding maximum plasma  
concentration ( Cmax), time for Cmax ( Tmax), area under the plasma concentration -time curve 
from time 0 to last  quantifiable concentration ( AUClast), area under the plasma conce ntration-
time curve from time 0 extrapolated to infinite time ( AUCinf), terminal plasma elimination 
half-life
 (t1/2), clearance ( CL), and volume  of distribution ( Vz) will be estimated using non -
compartmental analysis if data permit.  The effect of pal bociclib on total paclitaxel PK will 
be evaluated by determining the ratios of adjusted geometric means (nab -paclitaxel  in 
combina
tion with palbociclib/nab -paclitaxel  alone) and 90% CIs for the ratios (AUC inf and 
Cmax). 

3URWRFRO$ 6WDWLVWLFDO$QDO\VLV3ODQ9


3DJH8.2.6.3.Analysis of Pharmacokinetic endpoints 
)RUERWKSDOERFLFOLEDQGQDESDFOLWD[HO FRQFHQWUDWLRQVFRQFHQW UDWLRQVZLOOEHVXPPDUL]HG
GHVFULSWLYHO\QPHDQ6'FRH IILFLHQWRIYDULDWLRQ&9PHGL DQPLQLPXPPD[LPXP
JHRPHWULFPHDQDQGLWVDVVRFLDWHG&9E\GRVHFRKRUWF\FOHGD \DQGQRPLQDOWLPH
,QGLYLGXDOSDWLHQWDQGPHGLDQSURILOHVRIWK HFRQFHQWUDWLRQWLP HGDWDZLOOEHSORWWHGE\
GRVHFRKRUWF\FOHDQGGD\XVLQJQRPL QDOWLPHV0HGLDQSURIL OHVZLOOEHSUHVHQWHGRQERWK
OLQHDUOLQHDUDQGORJOLQHDUVFDOHV
)RUERWKSDOERFLFOLEDQGWRWDOSDFOLWD[HO3.SDUDPHWHUVZLOOE HVXPPDUL]HGGHVFULSWLYHO\E\
WUHDWPHQWGD\)RUWRWDOSDFOL WD[HOVWDWLVWLFDOVXPPDU\RIWU HDWPHQWFRPSDULVRQQDE
SDFOLWD[HOJLYHQLQFRPELQDWLRQZLWKSDOERFLFOLEYVQDESDFOLW D[HOJLYHQDORQHZLOODOVREH
SURYLGHG
)RUSDWLHQWVZKRKDGGRVHUHGXFWL RQGXULQJWKHWUHDWPHQWDQG3. VDPSOHVZHUHFROOHFWHG
DIWHUGRVHUHGXFWLRQGRVHQRUPDOL] HGFRQFHQWUDWLRQVDQG3.SDU DPHWHUVIRUWKHVHSDWLHQWV
PD\EHJHQHUDWHGDQGXVHGIRUWKHDQDO\VLV
)RUERWKSDOERFLFOLEDQGWRWDOSDFOLWD [HOGRVHQRUPDOL]HG$8& ƒ≤$8&LQIIRUWRWDOSDFOLWD[HO
DQG&PD[ZLOOEHSORWWHGDJDLQVWGRVHXVLQJDORJDULWKPLFVFDOHE\GD \7KHVHSORWVZLOO
LQFOXGHLQGLYLGXDOSDWLHQWYDOXHVDQGWKH JHRPHWULFPHDQVIRUH DFKGRVH7KHVHSORWVZLOOEH
XVHGWRKHOSXQGHUVWDQGWKHUHODWLRQV KLSEHWZHHQWKH3.SDUDPHW HUVDQGGRVH
8.2.6.4.Population Pharmacokinetic Analysi s or Pharmacokinetic/Pharmaco dynamic 
Modeling  
3KDUPDFRNLQHWLF3.DQGSKDUPDFR G\QDPLF3'GDWDIURPWKLVVW XG\PD\EHDQDO\]HG
XVLQJPRGHOLQJDSSURDFKHVDQGPD\DOVREHSRROHGZLWKGDWDIURP RWKHUVWXGLHVWR
LQYHVWLJDWHDQ\DVVRFLDWLRQEHWZ HHQSDOERFLFOLEH[SRVXUHDQGEL RPDUNHUVRUVLJQLILFDQWVDIHW\
HQGSRLQWV7KHUHVXOWVRI WKHVHDQDO\VHVLISHUIRUPHGPD\EH UHSRUWHGVHSDUDWHO\
7KHUHODWLRQVKLSEHWZHHQSDOERFLFOL EH[SRVXUHDQG3'HQGSRLQWV VXFKDVS5EDQG 
DFWLYLW\ZLOOEHH[SORUHGLIGDWDSHUPLW
8.2.7.Analyses Biomarker Endpoints  
%LRPDUNHUVZLOOEHDVVHVVHGVHSDU DWHO\IRUVHUXPSODVPDDUFKL YDOWXPRUWLVVXHGHQRYR
WXPRUELRSVLHVDQG ,QHDFKFDVH VXPPDULHVRIEDVHOLQHOHYHOV FKDQJHVIURP
EDVHOLQHZKHUHDSSURSULD WHH[SUHVVLRQDQGPXWDWLRQZLOOEHU HSRUWHG)RUFRQWLQXRXV
YDULDEOHVVXPPDU\VWDWLVWLFVPD\LQFOXGHWKHPHDQUDWLRWRED VHOLQHVWDQGDUGGHYLDWLRQWK
PHGLDQDQGWKTXDUWLOH&9DQGPLQLPXPPD[LP XPOHYHOVRIELRPDUNHUPHDVXU HVIRU
FDWHJRULFDOYDULDEOHVVXPPDU\ PD\LQFOXGHQXPEHUDQGSHUFHQWDJ HRGGVUDWLRDV
DSSURSULDWH
)RUSDQG5EH[SUHVVLRQ LQWXPRUWLVVXHDWEDVHOLQHWKHUHO DWLRQVKLSRIWKHELRPDUNHUV
LQGLYLGXDOO\ZLWK3)6DQG26ZLOOEHH[SORUHGXVLQJJUDSKLFDO PHWKRGVVXFKDVER[SORWV
DWEDVHOLQH$VHQVLWLYLW\DQD O\VLVRISDEVHQWYVDQ\VWD LQLQJLQWHQVLW\OHYHOYV3)6ZLOO
EHSHUIRUPHGERWKJUDSKLFDOO\ER[SORWVDQGVXPPDU\VWDWLVWLF VDQDO\VLVVXFKDVSDVD
FRYDULDWHLQD&R[PRGHO 5HFHLYHU2SHUDWLQJ&KDUDFWHULVWLF5 2&FXUYHDQDO\VLVZLOOEHCC
I
CCI
3URWRFRO$ 6WDWLVWLFDO$QDO\VLV3ODQ9


3DJHSHUIRUPHGXVLQJWKHEDVHOLQHELRP DUNHUVDVSUHGLFWRUVRI3)6DQ G26WKHDUHDXQGHUWKH
FXUYH$8&ZLOOEHFDOFXODWHG&XUYHVZLOOEHSURGXFHGIRUPH GLDQ3)6DQG26WLPHV
DORQJZLWKPRQWKVEHIRUHPHGLDQPRQWKVEHIRUHPHGLDQPR QWKVDIWHUPHGLDQDQG
PRQWKVDIWHUPHGLDQ,ILQFUHD VLQJYDOXHVRIWKHELRPDUNHUOHD GWREHWWHU3)626UHVSRQVH
WKHDFWXDOYDOXHRIWKHELRPDU NHUZLOOEHXVHG LQWKH52&DQDO\ VLV,ILQFUHDVLQJYDOXHVRI
WKHELRPDUNHUOHDGWRZRUVH3)626 UHVSRQVHWKH52&DQDO\VLVZ LOOXVHWKHLQYHUVHRIWKH
ELRPDUNHUYDOXHZLWKEHLQJVHWWR 7KHELRPDUNHUYDOXHZK LFKSURGXFHVWKHPD[LPDO
VHQVLWLYLW\VSHFLILFLW\SRLQWZLOOEHLGHQWLILHGIRUHDFKFXU YH








'DWDIURPELRPDUNHUDVVD\VZLOOEHDQDO\]HGXVLQJJUDSKLFDOPHW KRGVDQGGHVFULSWLYH
VWDWLVWLFVVXFKDVOLQHDUUHJ UHVVLRQWWHVWDQGDQDO\VLVRIY DULDQFH$129$7KHVWDWLVWLFDO
DSSURDFKPD\H[DPLQHFRUUHODWLRQVRIELRPDUNHUUHVXOWVZLWKSKD UPDFRNLQHWLFSDUDPHWHUV
DQGPHDVXUHVRIDQWLWXPRUHIILFDF\


















  
CCI
CCICCI
CCI
3URWRFRO$ 6WDWLVWLFDO$QDO\VLV3ODQ9


3DJH 
























7LPHWRHYHQWHQGSRLQWV
7LPHWRGHWHULRUDWLRQ77' LQ*OREDO42/LVGHILQHGDVWKHWLP HIURPUDQGRPL]DWLRQWRWKH
ILUVWWLPHWKHSDWLHQW¬∂VVFRUHVKRZVD SRLQWRUKLJKHUGHFUH DVHLQWKHJOREDO42/VXEVFDOH
VFRUHRIWKH4/4&3D WLHQWVZKRGRQRWKDYHD 77'HYHQWXS WRWKHWLPHRISURJUHVVLRQ
ZLOOEHFHQVRUHGRQWKHGDWHZKH QWKH\ODVWFRPSOHWHGWKH352D VVHVVPHQWRUDWHQGRI
WUHDWPHQWLIWKDWRFFXUVSULRUWRSURJUHVVLRQ
.DSODQ0HLHUHVWLPDWHVZLOOEH SUHVHQWHGWRJHWKHUZLWKDVXPPDU \RIDVVRFLDWHGVWDWLVWLFV
LQFOXGLQJWKHPHGLDQ77'WLPHZLWK VLGHG&,V7KH&,VIR UWKHPHGLDQZLOOEH
FDOFXODWHGDFFRUGLQJWR%URRNPH\HUDQG&URZOH\

CCI
CCI
Protocol A5481059 Statistical Analysis Plan V4 
 
 
Page 44 8.3. Summary of Key Clinical Efficacy Analyses  
Type of Analysis  Endpoint  Analysis Set  Statistical Method  
Secondary  
 ORR, CBR  Evaluable  (All,  
MTD expansion , 
MTD arm + MTD 
expansion ),   
Investigator 
assessment s  
(See 8.2.4. ) Exact CI based on Clopper -Pearson method (95% 
CI)  
Secondary  
 DR Evaluable  (All,  
MTD expansion,  
MTD arm + MTD 
expansion ),   
patients with a 
CR or PR  
Investigator 
assessments  
(See 8.2.4. ) K-M method (median and 95% CI)  
Secondary  PFS Safety analysis 
set (All, MTD 
expansion, MTD 
arm + MTD 
expansion ), 
Investigator 
assessment  
(See 8.2.4. ) K-M method (median and 95% CI)  
 
Secondary  OS Safety analysis 
set (All, MTD 
expansion, MTD 
arm + MTD 
expansion ) 
(See 8.2.4.) K-M method (median and 95% CI)  
 
Abbreviations: 
Evaluable : Per Protocol Analysis Set Evaluable for Anti-tumor Activities ; MTD expansion cohort is a subset of 
Evaluable.  
DR: duration of response; OR: objective response; OS: overall survival; PFS: progression-free survival.

Protocol A5481059 Statistical Analysis Plan V4 
 
 
Page 45 9. REFERENCES  
1. B
rookmeyer R, Crowley JJ.  A confidence interval for the median survival time.  Biometrics 
1982; 38:29-41. 
2. Cox DR. Regression models and life-tables (with discussion). Journal of the Royal Statistical 
Society, Series B 1972; 34:187-220.  
3. Eisenh
auer E, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, 
Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. 
New response evaluation criteria in solid tumors: Revised RECIST guideline version 1.1. Eur J 
Can 45: 228-47, 2009. 
4. Kaplan EL, Meier P.  Nonparametric estimation from incomplete observations.  J Am Stat Assoc 
1958; 53:457-481. 
5. ICH Harmonised Tripartite Guideline. The Clinical Evaluation of QT/QTc Interval Prolongation 
and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. E 14. May 12, 2005. 
6. National Cancer Institute (NCI). Common Terminology Criteria For Adverse Events (CTCAE). 
http://evs.nci.nih.gov/ftp1/CTCAE/About.html  
7. Sprangers MAG, Groenvold M, Arraras JL, et. Al. The European Organization for Research and 
Treatment of Cancer Breast Cancer -Specific Quality -of-Life Ques tionnaire Module: First Results 
From a Three -Country Fiel d Study. J Clin Oncol 1996; 14(10): 2756 -2768. 
8. Ji Y, Liu P, Li Y, and Bekele BN. A modified toxicity probability interval method for 
dose-
finding trials. Clinical Trials 2010 ; 7:653 663. 
9. Dykstra R, Robertson T. An algorithm for isotonic regression for two or more 
independe
nt variables. Ann Stat. 1982; 10:708-716.  

Protocol A5481059 Statistical Analysis Plan V4 
 
 
Page 46 10. APPENDICES  
10.1. Criteria for Dose Escalation 
Dose escalation will start from DL 1.  The sequential dose escalation scheme and the rules 
for determining dose escalation, de-escalation, or ‚Äòstay‚Äô (i.e. enroll an additional group of 
patients to the current DL) at any given dose level are described in the following paragraph 
and are illustrated in Figure 3.  
Starti
ng from DL1:  
ÔÇ∑ Once DL 1 has been found to be tolerable, DL 2A and DL 2B will be evaluated in 
para
llel.    
ÔÇ∑ If dose de-escalation is required at DL 1, then DL -1 will be evaluated next.   
The following rules apply if escalation to DL 2A and DL 2B will be explored: 
ÔÇ∑ If both DL 2A and DL 2B are tolerated and further dose escalation is considered, then 
DL 3A and DL 3B will be evaluated in parallel.      
ÔÇ∑ If DL 2A is tolerated and further dose escalation is recommended, but no dose 
escalation is determined from DL 2B, then only DL 3A will be evaluated as the 
subsequent dose escalation step.     
ÔÇ∑ If DL 2B is tolerated, but no dose escalation is determined at DL 2A, then no further 
dose e
scalation will be performed and DL 2B will be expanded to 9 patients, unless 
alrea
dy done, in order to determine the MTD.     
ÔÇ∑ If no dose escalation is determined at DL 2A and DL 2B, then no further dose 
escalation will be performed and DL 1 will be re-evaluated (expanded up to 9 
patients, unless already done, in order to enable a dose escalation or de-escalation 
decision).    
ÔÇ∑ If dose de-escalation is recommended after DL 2A, then DL 1 will be re -evaluated  ( 
ex
panded up to 9 patients, unless already done, in order to enable a dose escalation or 
de-e
scalation decision).   
ÔÇ∑ If dose de-escalation is recommended after DL 2B, then DL 1.5 will be evaluated. 
If
 dose escalation to DL 3A and DL 3B will be explored:  
ÔÇ∑ If further dose escalations are recommended at both DL 3A and DL 3B, then DL 4 
will be evaluated.      
ÔÇ∑ If dose escalation is recommended only at DL 3A or DL 3B, then no further dose 
escalation will be performed and DL 3A or DL 3B will be expanded to 9 patients, 
unless already done, in order to determine the MTD.    
ÔÇ∑ If dose de-escalation is recommended after both DL 3A and DL 3B, or after DL 3B 
only, then D
L 2A and DL 2B will be re-evaluated (expanded up to 9 patients, unless 
alrea
dy done, in order to enable a dose escalation or de-escalation decision; the order 
of the evaluation will be determined based on the toxicities observed from DL 2A and 
DL 2B).   

Protocol A5481059 Statistical Analysis Plan V4 
 
 
Page 47 ÔÇ∑ If dose de-escalation is only recommended after DL 3A (but not at DL 3B), then DL 
2A wil
l be re-evaluated (expanded up to 9 patients, unless already done, in order to 
enable a
 dose escalation or de-escalation decision). 
If dose
 escalation to DL 3A will only be explored:  
ÔÇ∑ DL 4 will not be evaluated regardless of the outcome at DL3A.      
ÔÇ∑ I
f dose de-escalation is recommended at DL 3A, then DL 2A will be re-e valuated 
(expanded up to 9 patients, unless already done, in order to enable a dose escalation 
or de-
escalation decision).   
If dose
 escalation to DL 4:  
ÔÇ∑ Dose escalation will be stopped at this DL. 
ÔÇ∑ If dose de-escalation is recommended after DL 4, then DL 3A and DL 3B will be re-
eva
luated (expanded up to 9 patients, unless already done, in order to enable a dose 
esca
lation or de-escalation decision; the order of the evaluation will be determined 
based on the tox
icities observed at DL 3A and DL 3B). 
If de-escalation to DL -1:  
ÔÇ∑ If dose escalation is determined from DL-1, then DL 1 will be re-evaluated (expanded 
up to 9 patients, unless already done, in order to enable a dose escalation or de-
esca
lation decision). 
ÔÇ∑ If dose de-escalation is determined from DL -1, the study will be terminated. 
Thre
e (3) patients per group will be initially treated at any given combination DL. Up to 3 
groups for a total of 9 patients can be treated at the same DL. Figure 10.1 illustrates the 
gen
eral dose escalation and de-escalation schema with a group size of 3 patients for a given 
DL based on this method. Detailed dose re-escalation and de-escalation schemas for a 
previous
 DL are provided in Figures 10.2 -10.5. 
  

Protocol A5481059 Statistical Analysis Plan V4 
 
 
Page 48 Figure 10.1 The General Dose Escalation and De-Escalation Schema with a Group Size 
of 3 Pat
ients at a Given Dose Level 
‚â•2 DLTs3 Patients 
(1 group)
1 DLT
2 DLTs0 DLT
6 patients
(2 groups)
‚â•3 DLTs 1 DLT
9 patients
(3 groups)
‚â•3 DLTs 2 DLTsDe-escalate to 
the previous 
dose levelEscalate to 
the next dose 
level
 
Note: In the figure, the term ‚ÄúDLT‚Äù means ‚Äúpatients with DLT‚Äù, not the actual number of DLT 
events. 
 
Initially a group of 3 patients will be enrolled at the starting DL.  When all 3 patients are 
available for DLT assessment, the number of patients with DLT(s) will inform the decision 
for the nex
t step: 
ÔÇ∑ If 0 patient with a DLT out of 3 evaluable patients, escalate. 
ÔÇ∑ I
f 1 patient with a DLT out of 3 evaluable patients, stay. 
ÔÇ∑ I
f 2 patients with a DLT out of 3 evaluable patients, de-escalate. 
ÔÇ∑ I
f 3 patients with a DLT out of 3 evaluable patients, stop the dose escalation. 
Ba
sed on the decision above, a second group of 3 patients will be enrolled at the 
corresponding DL.  Upon completion of the second group, a decision will be made again to 
eithe
r escalate, de-escalate, or stay. Table 8.1 is derived from a generalized approach that 
extends the current mTPI method and preserves its decision-theoretical properties.  
There are two scenarios under the decision of de-escalation: de-escalate and revisit allowed 
or de-escalate and revisit not allowed.  The latter means that the current DL is determined to 
be unacceptably toxic; this DL and the subsequent higher DLs will be excluded from the 
study. 
 
The decision-making needs to consider all patients treated at the current DL under 
evaluation.  For example, if the decision is to stay at the starting DL after the first group of 3 
patients (i.e. there is 1 patient with a DLT), and another group of 3 additional patients is 

Protocol A5481059 Statistical Analysis Plan V4 
 
 
Page 49 enrolled at the same DL, the next decision will be made based on all 6 patients treated at that 
DL: 
ÔÇ∑ If 1 patient experiences a DLT out of 6 evaluable patients, escalate. 
ÔÇ∑ I
f 2 patients experience a DLT out of 6 evaluable patients, stay. 
ÔÇ∑ If ‚â•3 patients experience a DLT out of 6 evaluable patients, stop the dose escalation. 
Dose escalation will continue until at least 9 patients have been treated at any given DL.  
Doses will not be escalated if the starting DL is deemed overly toxic, or if reaching the 
maximum 
sample size of approximately 30 patients is reached (i.e. the number of DLT-
evaluable patients).     
The MTD determination will be based on the observed toxicity rates among all evaluable 
patients at any given DL.  When dose escalation is stopped, the highest DL with an observed 
DLT rate <33% (in at least 9 DLT-evaluable patients) will be considered the MTD.  It is 
possible that more than one MTD will be determined, in which case a decision will be made 
to expand one or both MTDs in order to determine the RP2D.     
The gene
ral approach to dose-finding, using the mTPI method, involves the following: 
ÔÇ∑ The target group size is 3. However, patients can be enrolled in group sizes of 2-4 
pati
ents if necessary, depending on the number of potential patients identified at 
participating sites (see Table 8.1);   
ÔÇ∑ The next group of patients can be enrolled when all patients at a given  DL have been 
eva
luated for 28 days in the first treatment cycle, or any of the patients experience a 
DLT, whichever comes first; 
ÔÇ∑ If a patient withdraws from the study before having received >80% of the planned 
first
-cycle dose for palbociclib and nab-P for reasons other than investigational 
product-related toxicity, another patient will be enrolled to replace that patient at the 
current DL; 
The dose escalation portion of the study is completed when at least 9 evaluable patients have 
been tre
ated at the highest DL associated with a DLT rate <33%. It is estimated that 
approxim
ately 30 ‚ÄòDLT-evaluable‚Äô patients will be enrolled to reach n = 9 ‚ÄòDLT-evaluable‚Äô 
pati
ents at the estimated MTD. 
Dose escalation may be completed without determining the MTD based on emerging safety 
data, and upon agreement between the investigators and the sponsor. 
 
The RP2D will be determined in the MTD dose expansion cohort(s), taking into account the 
MTD(s) from the dose-escalation component, and other factors related to safety, efficacy, 
and PK/PD involving all available data from all tested DLs.  

Protocol A5481059 Statistical Analysis Plan V4 
 
 
Page 50 Figure 10.2 Dose de-escalation scheme to a previous dose level where 3 patients have 
bee
n treated with 0 DLT 
 
 
 
 
Figure 10.3 Dose de-escalation scheme to a previous dose level where 6 patients have 
bee
n treated with ‚â§1 DLT 
De-escalate to 
6 patients 
with ‚â§1 DLT
9 patients
(3 groups)
‚â•3 DLTs ‚â§2 DLTsRe-Escalate 
to the next 
dose levelDe-escalate to 
the previous 
dose level
 
 

Protocol A5481059 Statistical Analysis Plan V4 
 
 
Page 51 Figure 10.4 Dose re-escalation scheme from a previous dose level where 3 patients have 
bee
n treated with 2 DLTs 
 
 
Figure 10.5 Dose re-escalation scheme from a previous dose level where 6 patients have 
bee
n treated with 3 DLTs 
Escalate from 
6 patients 
with 3 DLTs
Stop
 
  

Protocol A5481059 Statistical Analysis Plan V4 
 
 
Page 52 10.2. RECIST (Response Evaluation Criteria in Soli d Tumors) version 1.1 Guidelines 
Adapted from  E.A. Eisenhauer, et al: New response evaluation criteria in solid tumours: 
Revised RE
CIST guideline (version 1.1). European Journal of Cancer 45 (2009) 228‚Äì247  
CATE
GORIZING LESIONS AT BASELINE 
Measu
rable Lesions   
Lesions that can be accurately measured in at least one dimension. 
ÔÇ∑ Lesions with longest diameter twice the slice thickness and at least 10 mm or greater  
when assessed by CT or MRI  (slice thickness 5-8 mm) 
ÔÇ∑ Lesions with longest diameter at  least 20 mm when assessed by Chest X-ray   
ÔÇ∑ Superficial lesions with longest diameter 10 mm or greater when assessed by caliper   
ÔÇ∑ Malig
nant lymph nodes with the short axis 15 mm or greater when assessed by CT. 
NOTE:  The
 shortest axis is used as the diameter for malignant lymph nodes, longest axis for 
all other measurable lesions.  
Non-measurable disease  
Non-measurable disease includes lesions too small to be considered measurable (including 
nodes with short axis between 10 and 14.9 mm) and truly non-measurable disease such as 
pleural or pericardial effusions, ascites, inflammatory breast disease, leptomeningeal disease, 
lymphangitic involvement of skin or lung, clinical lesions that cannot be accurately measured 
with calipers, abdominal masses identified by physical examination that are not measurable 
by r
eproducible imaging techniques. 
ÔÇ∑ Bone disease:  Bone disease is non-measurable with the exception of soft tissue 
components t
hat can be evaluated by CT or MRI and meet the definition of measurability 
at baseline.   
ÔÇ∑ Previous local treatment: A previously irradiated lesion (or lesion subjected to other local 
trea
tment) is non-measurable unless it has progressed since completion of treatment. 
Normal sites 
ÔÇ∑ Cystic lesions: Simple cysts should not be considered as malignant lesions and should not 
be recorded either as target or non-target disease.  Cystic lesions thought to represent 
cystic metastases can be measurable lesions, if they meet the specific definition above. If 
non-cystic lesions are also present, these are preferred as target lesions. 
ÔÇ∑ Normal nodes: Nodes with short axis <10 mm are considered normal and should not be 
recorded or followed either as measurable or non-measurable disease. 
RECORDING TUMOR ASSESSMENTS  
All sites of disease must be assessed at baseline.  Baseline assessments should be done as 
close as possible prior to study start. For an adequate baseline assessment, all required scans 
must be done within 28 days prior to treatment and all disease must be documented 

Protocol A5481059 Statistical Analysis Plan V4 
 
 
Page 53 appropriately. If baseline assessment is inadequate, subsequent statuses generally should be 
indeterminate.   
Target lesions 
All measurable lesions up to a maximum of 2 lesions per organ, 5 lesions in total, 
repre
sentative of all involved organs, should be identified as target lesions at baseline. Target 
lesions should be selected on the basis of size (longest lesions) and suitability for accurate 
repeated measurements.  Record the longest diameter for each lesion, except in the case of 
pathological lymph nodes for which the short axis should be recorded.  The sum of the 
diameters (longest for non-nodal lesions, short axis for nodal lesions) for all target lesions at 
baseline will be the basis for comparison to assessments performed on study.  
ÔÇ∑  If two target lesions coalesce the measurement of the coalesced mass is used.  If a large 
targe
t lesion splits, the sum of the parts is used. 
ÔÇ∑ Measurements for target lesions that become small should continue to be recorded.  If a 
targe
t lesion becomes too small to measure, 0 mm should be recorded if the lesion is 
considered to have disappeared; otherwise a default value of 5 mm should be recorded.. 
NOTE: When nodal lesions decrease to <10 mm (normal), the actual measurement should 
still be recorded. 
Non-target disease  
All non-measurable disease is non-target. All measurable lesions not identified as target 
lesions are also included as non-target disease.  Measurements are not required but rather 
assessments will be expressed as ABSENT, INDETERMINATE, PRESENT/NOT 
INCREASED, INCREASED.  Multiple non-target lesions in one organ may be recorded as a 
single item on the case report form (e.g. ‚Äòmultiple enlarged pelvic lymph nodes‚Äô or ‚Äòmultiple 
liver metastases‚Äô). 
OBJECTIVE RESPONSE STATUS AT EACH EVALUATION. 
Disease sites must be assessed using the same technique as baseline, including consistent 
administration of contrast and timing of scanning.  If a change needs to be made the case 
must be discussed with the radiologist to determine if substitution is possible.  If not, 
subsequent objective statuses are indeterminate.   
Target disease 
ÔÇ∑ Complete Response (CR): Complete disappearance of all target lesions with the 
ex
ception of nodal disease.  All target nodes must decrease to normal size (short axis < 
10 mm).  All target lesions must be assessed. 
ÔÇ∑ Partial Response (PR): Greater than or equal to 30% decrease under baseline of the sum 
of diameters of all target measurable lesions.  The short diameter is used in the sum for 
target nodes, while the
 longest diameter is used in the sum for all other target lesions.  All 
target lesions must be assessed.   
ÔÇ∑ Stable: Does not qualify for CR, PR or Progression.  All target lesions must be assessed.  
Stable can follow PR only in the rare case that the sum increases by less than 20% from 

Protocol A5481059 Statistical Analysis Plan V4 
 
 
Page 54 the nadir, but enough that a previously documented 30% decrease no longer holds.   
ÔÇ∑ Objective Progression (PD):  20% increase in the sum of diameters of target measurable 
lesions above the smalle
st sum observed (over baseline if no decrease in the sum is 
observed during therapy), with a minimum absolute increase of 5 mm.   
ÔÇ∑ Indeterminate. Progression has not been documented, and  
ÔÇ∑ one
 or more target measurable lesions have not been assessed  
ÔÇ∑ or assessment methods used were inconsistent with those used at baseline 
ÔÇ∑ or
 one or more target lesions cannot be measured accurately (e.g., poorly visible 
unless due to being
 too small to measure) 
ÔÇ∑ or one or more target lesions were excised or irradiated and have not reappeared or 
increased.   
Non-target disease 
ÔÇ∑ CR: Disappearance of all non-target lesions and normalization of tumor marker levels. 
All ly
mph nodes must be ‚Äònormal‚Äô in size (<10 mm short axis). 
ÔÇ∑ Non-CR/Non-PD: Persistence of any non-target lesions and/or tumor marker level above 
the normal li
mits.  
ÔÇ∑ PD: Unequivocal progression of pre-existing lesions. Generally the overall tumor burden 
must increase sufficiently to merit discontinuation of therapy.  In the presence of SD or 
PR in target disease, progression due to unequivocal increase in non-target disease should 
be rare.   
ÔÇ∑ Indeterminate: Progression has not been determined and one or more non-target sites 
were
 not assessed or assessment methods were inconsistent with those used at baseline. 
New Lesions  
The appearance of any new unequivocal malignant lesion indicates PD.  If a new lesion is 
equivocal, for example due to its small size, continued assessment will clarify the etiology.  
If repeat assessments confirm the lesion, then progression should be recorded on the date of 
the initial assessment.  A lesion identified in an area not previously scanned will be 
considered a new lesion. 
Supplemental Investigations 
ÔÇ∑ If CR determination depends on a residual lesion that decreased in size but did not 
disappea
r completely, it is recommended the residual lesion be investigated with biopsy 
or fine needle aspirate.  If no disease is identified, objective status is CR. 
ÔÇ∑ If progression de termination depends on a lesion with an increase possibly due to 
necrosis, the lesion may be investigated with biopsy or fine needle aspirate to clarify 
status.  
Subjective progression 
Patients requiring discontinuation of treatment without objective evidence of disease 
progression should not be reported as PD on tumor assessment CRFs.  This should be 
indicated on the end of treatment CRF as off treatment due to Global Deterioration of Health 

Protocol A5481059 Statistical Analysis Plan V4 
 
 
Page 55 Status.  Every effort should be made to document objective progression even after 
discontinuation of treatment.   
Table 10.4. Objective Response Status at each Evaluation 
 
If the protocol allows enrollment of patients with only non-target disease, the following table 
will be used: 
 
Table 10.5. Objective Response Status at each Evaluation for Patients with Non-Target 
Disease Only 
 
BOR Based on Confirmed Responses 
CR:  Two objective statuses of CR a minimum of four weeks apart documented before 
progression and start of new anti-cancer therapy. 
PR:  Two objective statuses of PR or better (PR followed by PR or PR followed by CR) a 
minimum of four weeks apart documented before progression and start of new anti -cancer 
therapy, but not qualifying as CR.  Sequences of PR - Stable- PR are consi dere d PRs as long 
as the two PR
 responses are observed at a minimum of 4 weeks apart .    Target Lesions  Non-target Disease  New 
Lesions Objective 
status 
CR CR No CR 
CR Non-CR/Non-PD No PR 
CR Indeterminate or Missing  No PR 
PR Non-CR/Non-PD, 
Indeterminate, or Missing  No PR 
SD Non-CR/Non-PD, 
Indeterminate, or Missing  No Stable 
Indeterminate or Missing  Non-PD No Indeterminate  
PD Any Yes or No  PD 
Any PD Yes or No  PD 
Any Any Yes PD 
Non-target Disease  New Lesions  Objective status  
CR No CR 
Non-CR/Non-PD No Non-CR/Non-PD 
Indeterminate  No Indeterminate  
Unequivocal progression  Yes or No  PD 
Any Yes PD 

Protocol A5481059 Statistical Analysis Plan V4 
 
 
Page 56 SD:  At least one objective status of stable or better documented at least 6 weeks after start 
date and be
fore progression and the start of new anti-cancer therapy but not qualifying as CR 
or PR.   
PD:  Progression documented within 18 weeks after start date and not qualifying as CR, PR 
or SD.   
Not
 Evaluable (NE):   All other cases.  Note that reasons for NE should be summarized and 
the foll
owing reasons could be used:  
ÔÇ∑ Early death (Note: death < 6 we eks after start date)  
ÔÇ∑ No post-baseline assessments  
ÔÇ∑ All post-baseline assessments have overall response NE 
ÔÇ∑ Ne
w anti-cancer therapy started before first post-baseline assessment 
ÔÇ∑ SD too early (<6 weeks after start date) 
ÔÇ∑ P
D too late (>18 weeks after start date) 
Spec
ial and rare cases where BOR is NE due to both early SD and late PD will be 
classified as ‚ÄòSD too early‚Äô. 
An objective status of PR or SD cannot follow one of CR.  SD can follow PR only in the rare 
case that tumor increases by less than 20% from the nadir, but enough that a previously 
documented 30% decrease from baseline no longer holds.  If this occurs the sequence PR-
SD-PR is considered a confirmed PR.  A sequence of PR ‚Äì SD ‚Äì SD ‚Äì PD would be a best 
response of S
D if the window for SD definition has been met. 
The overall response rate  (ORR) is defined as the percentage of patients with a best overall 
response of C
R or PR relative to the appropriate analysis set.  

Protocol A5481059 Statistical Analysis Plan V4 
 
 
Page 57 10.3. Rules for Determining PFS Status and Date 
Situation Date of Progression/Censoring1 Outcome  
Inadequate baseline 
assessment  First dose  date (Day 1)2 Censored  
No on-study assessments  First dose  date (Day 1) 2 Censored  
Alive and no Progression  Date of last objective tumor assessment 
documenting no  progression Censored  
Progression Documented on 
or between scheduled tumor 
assessments Date of first objective tumor assessment 
documenting objective progression  
 Progressed 
(Event) 
Patients are r emoved from 
the study (withdrew the 
consent, lost to follow up, etc.)  
prior to progression or death  Date of last objective tumor assessment 
documenting no progression  Censored  
New anticancer treatment 
prior to progression  or death Date of last objective tumor assessment 
documenting no progression prior to 
new anticancer treatment  Censored  
Death prior to first planned 
tumor assessment  Date of death  Death (Event)                 
Death without objective 
progression prior to 
treatment discontinuation2 Date of death  Death (Event) 
                   
Death or progression after 2 
or more missed tumor 
assessments  Date of last objective tumor assessment 
documenting no progression prior to the 
event Censored  
1 For date of censorship, if a tumor assessment takes place over a number of days (e.g., superficial lesions one 
day, scans another), the first date is used as PD date and the last date is used as the other assessment date. 
1 First dose date is defined as the first Palbociclib dose date 
 

Protocol A5481059 Statistical Analysis Plan V4 
 
 
Page 58 10.4. Data Derivation Details 
Enrollment  Date of assignment of the randomization number  
Study Day 1  First dose  day  
 
Treatment -Palbociclib  start Day 1 of Cycle 1   
Treatment -nab-P start Day -2 of Cycle 1  
Day 1 (cycle start date) of Cycle x  Day 1 of a cycle is every 28 days unless there is a 
dosing delay.  
Cycle length (all but final cycle)  Cycle length is 28 days (previous cycle length may 
exceed planned length if there is a delay in study 
treatment administration).  
Final cycle  For patients off treatment, from Day 1 of final cycle to 
28 days after final dose or until start of new anticancer 
treatment (whichever comes first).   
For patients on treatment, from Day 1 of most recent 
cycle start to protocol specified cycle length.  
Follow-up Period for AEs  From 28 days after final dose until start of new 
anticancer treatment (whichever comes first).   
Baseline lab values  From date closest to, but prior to, start of study 
treatment.  
Baseline triplicate ECGs Cycle 1 Day -2 dose date or from date closest to, but 
prior to, start of any of study treatment s if C1D-2 is 
not available.  
Tumor assessment baseline values  From date closest but prior to first dose.   
Adequate baseline tumor 
assessment  Within 35 (28 + 7) days prior to first dose.  
Maximum diameter reported for each target lesion 
listed.  All required pre -treatment scans done.  
Cycle k treatment delayed.  If study treatment administration is delayed for cycle k 
then cycle k -1 is extended.  
 

Protocol A5481059 Statistical Analysis Plan V4 
 
 
Page 59 10.5. Study Treatment Modification and Compliance  
10.5.1. Dose M
odification 
In the e
vent of significant treatment-related toxicity, palbociclib and/or n ab-paclitaxel dosing 
may b
e interrupted or delayed and/or reduced as described below.  In the event of multiple 
toxicities, dose modification should be based on the worst toxicity observed.  Patients are to 
be instructed to notify Investigators at the first occurrence of any adverse sign or symptom. 
Dose modifications may occur in three ways: 
ÔÇ∑ Within a cycle: dosin g interruption  until adequate recovery and dose reduction , if 
required, during a given treatment cycle; 
ÔÇ∑ Between cycles: next cycle administration may be de layed due to persisting toxicity 
when a ne
w cycle is due to start; 
ÔÇ∑ In the next cycle: dose r eduction may be required in a subsequent cycle based on 
toxicity experienced in the previous cycle. 
10.5.2. Summarizing Relative Dose (RD) and Relative Dose Intensity (RDI)  
The following types of summaries are proposed for administration of palbociclib and nab -
paclitaxel. 
 
When 
palbociclib is administered orally once a day for 21 days of every 28-day cycle 
followed by
 7 days off treatment (cyclical dosing) in combination with nab -paclitaxel ( IV, 
D1, D8, D15)
, the following summaries can be present ed: 
 
ÔÇ∑ R
DI for palbociclib: by Cycle and Overall  
ÔÇ∑ R
DI for nab-paclitaxel: by Cycle and Overall 
 
When palbociclib is administered orally daily in combination with nab -paclitaxel (IV, D1, 
D15) a
nd uses 28 days as a cycle definition, the following summaries can be present ed: 
 
ÔÇ∑ RDI
 for palbociclib: by Cycle and Overall 
ÔÇ∑ RDI for n ab-paclitaxel: by Cycle and Overall 
 
Note: the denominator for tables summarizing ‚Äún ab-paclitaxel‚Äù will be all patients who 
received at least one dose of n ab-paclitaxel and for tables summarizing ‚Äúpalbociclib‚Äù will be 
all pa
tients who took at least one dose of palbociclib. 
 
Examples for the summaries described in above are included in the tables below. 
 
Conventions: 
ÔÇ∑ The Intended Daily Dose is the same for all cycles: the daily dose is fixed at the start of 
treatm
ent rather than start of a cycle and the intended treatment duration is the same for 

Protocol A5481059 Statistical Analysis Plan V4 
 
 
Page 60 the entire dosing period (e.g. for a 3/1 dosing schedule, all non-last cycles have an 
intende
d duration of 4 weeks. The intended treatment duration for the last cycle is from 
the 1st dose date of the last cycle to the EOT date or duration of 4 weeks which is 
shorter); 
 
ÔÇ∑ Actual Dose Intensity is calculated based on actual cycle length  

Protocol A5481059 Statistical Analysis Plan V4 
 
 
Page 61 Table 10.6 Cyclical Palbociclib By Cycle 
Treatment / 
Summary 
Type  Calculation of RDI  
Cyclical 
palbociclib  
(3/1) or 
continued / 
By Cycle  
 
 
                                        
 
100 *ilyDose IntendedDasity yDoseInten ActualDailRDIÔÄΩ
% 
% 
Where: 
Intended Daily Dose  (mg/day in 21/7 schedule or continued schedule ) = 
75, 100, 125  
 
Actual Daily Dose Intensity  (mg/day in 21/7 schedule) =  
      Actual Average Daily Dose (mg/day in x/y schedule) *  
     (Actual Dose Days / Intended Dose Days ) *  
     (Intended Cycle Duration / Actual Cycle Duration)  
   
ÔÇ∑ Actual Average Daily Dose  (mg/day in x/y schedule) =  
             Actual Total Dose  / Actual Dose Days   
ÔÇ∑ Intended Dose Days  = 
ÔÅ∂ For 3/1 schedule:  
                    For  non-last cycle: 21  
       For last cycle: minimum (21, ( Decision date of stopping trt from 
EOT page  -1st dose date in last cycle +1))  
ÔÅ∂ For continued schedule:  
                    For  non-last cycle: 28  
       For last cycle: minimum (28, ( Decision date of stopping trt from 
EOT page  -1st dose date in last cycle+1))  
 
ÔÇ∑ Intended Cycle Duration  =  
For non-last cycle: 28  
      For last cycle: minimum (28, ( Decision date of stopping trt from EOT 
page -1st dose date in last cycle+1))  
 
ÔÇ∑ Actual Cycle Duration for last cycle = 
o For non-last cycle: Next cycle‚Äôs Day 1 date ‚Äì Current cycle‚Äôs 
Day 1 date   
o For last cycle: (Min [Decision date of stopping trt from EOT 
page, EOS date]   - 1st dose date in last cycle  +1                    )  
 

Protocol A5481059 Statistical Analysis Plan V4 
 
 
Page 62 Table 10.7 Cyclical Palbociclib Overall 
Treatment / 
Summary 
Type  Calculation of RD/RDI  
Cyclical 
palbociclib  / 
Overall  
 
 
 
100*ilyDose IntendedDasity yDoseInten ActualDailRDIÔÄΩ% 
% 
Where: 
Intended Daily Dose  (mg/day in 21/7 schedule or continued schedule ) = 
75, 100, 125  
 
 
Actual Daily Dose Intensity  (mg/day in 21/7 schedule  or continued 
schedule ) =  
      Actual Average Daily Dose (mg/day in x/y schedule) *  
     (Actual Dose Days / Intended Dose Days ) *  
     (Intended Cycle Duration / Actual Cycle Duration)  
   
ÔÇ∑ Actual Average Daily Dose (mg/day in x/y schedule) =  
Sum over all cycles of ‚Äú Actual Total Dose‚Äù /  
Sum over all cycles of ‚Äú Actual Dose Days ‚Äù 
  
ÔÇ∑ Actual Dose Days = Sum over all cycles of ‚ÄúActual Dose Days‚Äù   
ÔÇ∑ Intended Dose Days = Sum over all cycles of ‚ÄúIntended Dose Days‚Äù  
ÔÇ∑ Actual Cycle Duration = Sum over all cycles of ‚ÄúActual Cycle 
Duration‚Äù  
ÔÇ∑ Intended Cycle Duration = Sum over all cycles of  ‚ÄúIntended Cycle 
Duration‚Äù  
 
 
 
 
 

Protocol A5481059 Statistical Analysis Plan V4 
 
 
Page 63   
Table 10.
8 Nab-paclitaxel by Cycle and Overall 
Treatment  (Schedule) / Summary Type  Calculation of Relative Dose Intensity (RDI)  
Nab-P (3/1 or Biweekly)   
/ By Cycle 
 
 
100 *erageDose IntendedAvIntensity ActualDoseRDIÔÄΩ% 
% 
Where: 
Intended Average Dose  (mg/Q7d) = {100                                                                                         for DL1, DL2A, DL3A, MDR2
125                                                                                         for DL2B, DL3B, DL4, MDR1
 ùë†ùëéùëöùëí ùëéùë† ùë°‚Ñéùëíùëñùëü ùëúùëüùëñùëîùëñùëõùëéùëô ùëëùëúùë†ùëí ùëêùëú‚Ñéùëúùëüùë°               ùëúùëõ ùë°‚Ñéùëí ùëÄùëáùê∑ ùëúùëü ùëÄùê∑ùëÖ ùê∏ùë•ùëùùëéùëõùë†ùëñùëúùëõ   
Actual Dose Intensity  (mg/Q7d in planned schedule ) =  
      Actual Average Dose each time (mg/Qxd) in the Cycle  
      * (Actual Freq in the Cycle/ Intended Freq in the Cycle)    
      * (Intended Cycle Duration/ Actual Cycle Duration)  
ÔÇ∑ Factor in dose reductions or potential overdose:   
Actual Average Dose each time (mg/Qxd) in the Cycle =  
             Actual Total Dose in the Cycle / Actual Freq in the Cycle   
ÔÇ∑ Factor in dose interruptions:  
Actual freq on Drug / Intended Freq on Drug  
ÔÇ∑ Factor in cycle delays:  
      Intended Cycle Duration / Actual Cycle Duration  
ÔÇ∑ Intended Freq on Drug in each Cycle 
 
{      
 2                                                                                             for non -last Cycle in MDR1, MDR2, MDR Expansion
3                                                  for non -last cycle in DL1,  DL2A, DL2B, DL3A, DL3B, DL4, MTD, MTD Expansion
1                                               for last Cycle and its actual cycle duration ‚â§ 14 in MDR1, MDR2, MDR Expansio n
2                                                for last Cycle and its actual cyc le duration > 14 in MDR1, MDR2, MDR Expansion
1    for last cycle and actual cycle duration ‚â§ 5 in DL1, DL2A, DL2B, DL3A, DL3B, DL4, MTD, MTD Expansion
2    for last cycle and actual cycle duration ‚â§10 in DL1, DL2A, DL2B, DL3A, DL3B, DL4, MTD, MTD Expansion
3    for last cycle and actual cycle duration ‚â§ 17 in DL1, DL2A, DL2B, DL3A, DL3B, DL4, MTD, MTD Expansion 
ÔÇ∑ Intended Cycle Duration =  {28                                                   for non -last cycle
min(28, Actual last Cycle Duration )    for last cycle 
ÔÇ∑ Actual Cycle Duration = 

Protocol A5481059 Statistical Analysis Plan V4 
 
 
Page 64 {(Day 1 of next cycle - Day 1 of of current cycle)                                                                                 for non -last cycle
max(nabP EOT date,NabP last dose date from dose page)‚Äì 1st day of the last cycle +1        for last cycle 
 

Protocol A5481059 Statistical Analysis Plan V4 
 
 
Page 65 Nab-P (3/1 or Biweekly)   
/ Overall 
 
 
 
100 *erageDose IntendedAvIntensity ActualDoseRDIÔÄΩ% 
% 
Where: 
Intended Average Dose  (mg/Q7d) = {100                                                                                         for DL1, DL2A, DL3A, MDR2
125                                                                                         for DL2B, DL3B, DL4, MDR1
 ùë†ùëéùëöùëí ùëéùë† ùë°‚Ñéùëíùëñùëü ùëúùëüùëñùëîùëñùëõùëéùëô ùëëùëúùë†ùëí ùëêùëú‚Ñéùëúùëüùë°               ùëúùëõ ùë°‚Ñéùëí ùëÄùëáùê∑ ùëúùëü ùëÄùê∑ùëÖ ùê∏ùë•ùëùùëéùëõùë†ùëñùëúùëõ   
Actual Dose Intensity (mg/Q7d in planned schedule ) =  
      Actual Average Dose each time (mg/Qxd)  
      * (Actual Freq in the Cycle / Overall Intended Freq)    
      * (Intended Total Cycle Duration / Overall Actual  Cycle Duration ) 
 
ÔÇ∑ Factor in dose reductions or potential overdose:   
Actual Average Dose each time (mg/Qxd) =  
             Actual Total Dose / Actual Total Freq on Drug  
ÔÇ∑ Factor in dose interruptions:  
Actual Total Freq on Drug / Intended Total Freq on Drug  
ÔÇ∑ Factor in cycle delays:  
      Intended Total Cycle Duration / Actual Total Cycle Duration  
ÔÇ∑ Intended Total Freq on Drug:  
  
{         
For MDR1, MDR2, MDR Expansion Expansion:                                                                                
= 2*(total of non -last cycle) + (1 or 2 for last cycle based on following situation)              
1                                   for last Cycle and its actual cycle duration ‚â§ 14
2                                   for last Cycle and its actual cycle d uration > 14
For DL1, DL2A, DL2B, DL3A, DL3B, DL4, MTD, MTD Expansion:                                              
= 3*(total of non -last cycle) + (1 or 2 or 3 for last cycle based on following situation) 
1    for last cycle and actual cycle duration ‚â§ 5 
2    for last cycle and actual cycle duration ‚â§10
3    for last cycle and actual cycle duration ‚â§ 17 
ÔÇ∑ Intended Total Cycle Duration =  {28*(total of non -last cycle) + min(28, Actual last Cycle Duration ) 
ÔÇ∑ Actual Total Cycle Duration: max(decision date on stopping N abP from EOT page, NabP last dose date+6) ‚Äì Day 1 of Cycle 1 +1  

Protocol A5481059 Statistical Analysis Plan V4 
 
 
Page 66  
10.6. Karnofsky Performance Status 
 

3URWRFRO$ 6WDWLVWLFDO$QDO\VLV3ODQ9


3DJHCCI
3URWRFRO$ 6WDWLVWLFDO$QDO\VLV3ODQ9


3DJH
CCI
3URWRFRO$ 6WDWLVWLFDO$QDO\VLV3ODQ9


3DJH


CCI
Protocol A5481059 Statistical Analysis Plan V4 
 
 
Page 70 10.9. List of Abbreviation 
Abbreviat
ion Term 
AE adverse event  
AIDS acquired immunodeficiency syndrome   
ALT alanine aminotransferase  
ANC absolute neutrophil count  
ANOVA analysis of variance  
ASCO American Society of Clinical Oncology  
AST aspartate aminotransferase  
AUC area under the curve  
BID twice daily  
BP blood pressure  
BUN blood urea nitrogen  
C Cycle 
ÔÇ∞C degrees Celsius  
CHF congestive heart failure  
CI confidence interval  
CL Clearance  
CLIA Clinical Laboratory Improvement Amendments  
CNS central nervous system  
CR complete response  
CRF case report form  
CSA clinical study agreement  
CSF cerebrospinal fluid  
CSR clinical study report  
CT computed tomography  
CTA clinical trial application  
CTCAE Common Terminology Criteria for Adverse Events 
CV coefficient of variation  
D day 
DAI dosage and administration instructions  
DCT data collection tool  
DDI drug-drug interaction  
DEHP di-ethylhexylphthalate  
DL dose level  
DLT dose limiting toxicity  
DMC data monitoring committee  
DNA deoxyribonucleic acid  
DR Duration of Response  
EC ethics committee  
ECG electrocardiogram  
EDP exposure during pregnancy  
EDTA edetic acid (ethylenediaminetetraacetic acid)  

Protocol A5481059 Statistical Analysis Plan V4 
 
 
Page 71 eg for example  
ESoE Early Signs of Efficacy  
etc ‚Äòand other things‚Äô or ‚Äòand so forth‚Äô 
EudraCT European Clinical Trials Database  
FDA Food and Drug Administration (United States)  
FDAAA Food and Drug Administration Amendments Act (United States)  
FFPE formalin-fixed  paraffin -embedded  
FSH follicle-stimulating hormone  
g gravity 
GCP Good Clinical Practice  
G-CSF granulocyte -colony stimulation factor  
HBV hepatitis B virus  
HCV hepatitis C virus  
HDPE high-density polyethylene  
Hgb hemoglobin  
HIV human immunodeficiency virus  
HR hazard ratio  
IB investigator‚Äôs brochure  
IC50 concentration of an inhibitor where the response (or binding) is reduced by half  
ICH International Conference on Harmonisation  
ID identification  
ie that is 
IHC immunohistochemistry  
IND investigational new drug application  
INR international normalized  ratio 
IRB institutional review board  
IUD intrauterine device  
IP investigational product  
IV intravenous  
K2EDTA dipotassium ethylene diamine tetraacetic acid  
KPS Karnofsky performance status  
KRAS Kirsten rat sarcoma viral oncogene homolog  
LFT liver function test  
mTPI modified toxicity probability interval  
MAPK Mitogen-activated protein kinase  
MD multiple dose  
MedDRA  Medical Dictionary for Regulatory Activities  
MFD maximum feasible dose  
MID minimally important difference  
mPDAC Metastatic Pancreatic Ductal Adenocarcinoma  
MRI magnetic resonance imaging  
MTD maximum tolerated dose  
N/A not applicable  
Nab-P nanoparticle albumin -bound Paclitaxel  
NCI  National Cancer Institute  

Protocol A5481059 Statistical Analysis Plan V4 
 
 
Page 72 NGS Next Generation Sequencing  
NS not significant  
ORR overall response rate  
OS overall survival  
pT target probability  
PCD primary completion date  
PD pharmacodynamics  
PD progressive disease  
PDAC Pancreatic ductal adenocarcinoma  
PET positron emission tomography  
PFS progression -free survival  
PK pharmacokinetics  
PPI Proton-pump inhibitor  
PR partial response  
p-Rb1 Phosphorylated retinoblastoma protein  
PS performance status  
PT prothrombin time  
PTT partial thromboplastin time  
PVC plasticized polyvinyl chloride  
QD every day  
QT time between the start of the Q  wave and the end of the T wave  
R ratio 
RECIST Response Evaluation Criteria in Solid Tumors  
RFS Relapse-Free Survival  
RNA ribonucleic acid  
RP2D recommended Phase 2 dose  
SAE serious adverse event  
SAP statistical analysis plan  
SD stable disease  
SIB suicidal ideation and behavior  
SOA Schedule of Activities  
SPC Summary of Product Characteristics  
SRSD single reference safety document  
T Time 
T1/2 terminal elimination half -life 
TBR tumor background ratio  
TTD time to deterioration  
ULN upper limit of normal  
UPM unit probability mass  
US United States  
USPI United States Package Insert  
V volume of distribution  
WBC white blood cell  
 
